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 There is a saying that it takes a village to raise a child, and I think the same 
analogy can be applied to a person obtaining a Ph.D. It is a lengthy and challenging yet 
rewarding journey starting as a fresh-faced, naïve first year that wants to save the world, 
only to figure out that you will only contribute a small amount of information to the 
entirety of human knowledge. But the fun part is that you DO contribute something new 
and different to the greater scientific community with the hopes that it might one day lead 
to an important breakthrough.  
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major role in making GT what it is today. There are also the unsung heroes, the people 
who do all the grunt work in the background with little recognition. Meg, Colly, Floyd, 
and the other IBB staff have been fantastic to work with over the years, especially 
through my involvement in various leadership positions in BBUGS. The BME 
department staff, especially Shannon and Sally, has been extremely helpful with so many 
things from administrative questions to trying to find a job. IBB support staff keeps our 
core facilities running, take care of problems, and make sure everything runs smoothly in 
the building. The PRL staff has been great as well, taking care of our animals and making 
sure we have everything we need to succeed with our in vivo experiments. There are so 
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the time about brain stuff. Isaac, George, Jessica, Akhil, Tarun, Lohitash, and others have 
been very helpful in answering my many questions over the years. My first paper was 
published with a polymer developed in the Lyon lab with Toni South who was a great 
mentor when I was a new grad student trying to figure out all this new chemistry. Jeff 
Gaulding, Emily Herman, and Grant Hendrickson have also been a great help during my 
thesis. My work with the Collard lab has been interesting, starting with developing a new 
coating method with Katelyn. Although that project didn’t end up working out, I made 
some great friends in Katelyn and Guillermo. The Stanley lab was also very helpful when 
I was exploring the recording aspect of electrodes. Doug, Qi, and Daniel were all very 
patient as I tried to learn more about the recording system and I thank them for all of their 
help. Finally, JT in the LaPlaca lab has been extremely helpful over the years. He 
harvested all of the primary cells for my in vitro studies and was always there to share his 
expertise when I had a question, and there were many questions during my time here. I 
am immensely grateful for all of the help I have received from these people throughout 
my thesis. 
 Next, I would like to thank two of the people who set me on this journey. My 
senior project advisers at WPI, George Pins and Glenn Gaudette, were instrumental in my 
decision to go to grad school when I was weighing my post-graduation options as an 
undergrad. I wasn’t really sure if grad school was what I wanted to do with the next five 
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(six) years of my life, and it was a difficult decision. After being immersed in research 
with these two professors and after several soul-searching conversations, I was on the 
path to the Ph.D. I can’t thank them enough for their advice over 6 years ago.  
 Of course no grad student experience would be complete without other the other 
grad students in the program. I have had the opportunity to meet so many people while 
pursuing my PhD at Georgia Tech through BME, BioE, IBB, BBUGS, ORGT and other 
organizations. There are too many to list here, but each person I have met along the way 
has played some role, great or small, in my journey. There are a few people in particular 
that I would like to mention. Morris, I’ve had a great time climbing and kayaking with 
you. We’ve had some fun times through ORGT and on our own trips and I will miss the 
adventures. Hopefully I can come back to Atlanta to visit and we can go explore the 
outdoors together again! Patricia and Kristin – I’ve had many a great meal at your 
apartment, and you guys are a ton of fun. I wish you all the best with finishing your 
theses and as you move on in life. Tanu has been a good friend over the years, always 
good for a laugh whenever we brought up cats or kids. Simone and Nina brought the 
European perspective during their short time in the Garcia lab and we had a great time 
exploring Atlanta together.  
Alice, Si, Shu, and Tiffany, and Gen. We have spent the better part of five years 
together, and I wouldn’t change a minute of it. Together we’ve been through the good, 
the bad, and the ugly. We’ve complained about our advisers, our failed experiments, and 
our frustration with science. We’ve seen each other through hard times, but also 
celebrated some wonderful accomplishments. Passing quals, presenting successful 
proposals and dissertations, birthdays, best papers, and so many other things have filled 
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our lives. I knew I could always count on your guys to be there for me. We’ve explored 
Atlanta and its many food options, and you have expanded my palette in ways I never 
imagined before coming here. All those nights of tofu soup or Vietnamese or dumplings 
followed by hours spent talking over bubble tea – these were the best. I have never 
known a better group of friends and I hope we keep in touch as we all move on to bigger 
and better things.  
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Neural electrodes are an important part of brain-machine interface devices that 
can restore functionality to patients with sensory and movement impairments including 
spinal cord injury and limb loss. Currently, chronically implanted neural electrodes 
induce an unfavorable tissue response which includes inflammation, scar formation, and 
neuronal cell death, eventually causing loss of electrode functionality in the long term. 
The objective of this research was to develop a coating to improve the tissue response to 
implanted neural electrodes. The hypothesis was that coating the surface of neural 
electrodes with a non-fouling, anti-inflammatory coating would cause reduced 
inflammation and a better tissue response to the implanted electrode. We developed a 
polymer coating with non-fouling characteristics, incorporated an anti-inflammatory 
agent, and engineered a stimulus-responsive degradable portion for on-demand release of 
the anti-inflammatory agent in response to inflammatory stimuli. We characterized the 
coating using XPS and ellipsometry, and analyzed cell adhesion, cell spreading, and 
cytokine release in vitro. We analyzed the in vivo tissue response using 
immunohistochemistry and microarray qRT-PCR. Although no differences were 
observed among the samples for inflammatory cell markers, lower IgG penetration into 
the tissue around PEG + IL-1Ra coated electrodes suggests an improvement in BBB 
integrity. Gene expression analysis showed higher expression of IL-6 and MMP-2 around 
PEG + IL-1Ra samples, as well as an increase in CNTF expression, an important marker 
for neuronal survival. An important finding from this research is the increased neuronal 
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survival around coated electrodes compared to uncoated controls, which is a significant 
finding as neuronal survival near the implant interface is an essential part of maintaining 









 Neural electrodes are an essential part of brain-machine interfaces that can restore 
functionality to patients with spinal cord injury and limb loss. However, current tissue 
responses to implanted neural electrodes comprise inflammation, scar formation, and 
neuronal cell death. These adverse reactions severely reduce the ability of the electrode to 
receive electrical signals from surrounding neurons, thereby affecting long-term electrode 
functionality.  
 The objective of this project is to improve the tissue response to implanted neural 
electrodes. My central hypothesis is that coating implantable neural electrodes with a 
non-fouling coating will reduce cell adhesion and scar formation around the electrode. 
Additionally, by incorporating an anti-inflammatory agent we can modulate inflammation 
in the tissue at the electrode interface. 
Specific Aim 1: Analyze host response to microgel coatings on neural electrodes 
implanted in the brain. 
 We hypothesized that coating neural electrodes with a thermally-responsive 
poly(ethylene glycol) – N(isopropylacrylamide) – acrylic acid (PEG-NIPAm-acrylic 
acid) microgel coating would yield a biocompatible coating that would reduce scar 
formation and inflammation in the brain. We showed that the microgel coating is 
successfully applied to the surface and also that the coating does reduce cell adhesion in 
vitro. However, results from long-term in vivo implantation studies in the rat brain 
indicate that the coating alone is not sufficient to reduce scar formation and inflammation 
in this rat model. 
 2 
Specific Aim 2: Engineer protease-degradable PEG-maleimide coatings with on-
demand release of an anti-inflammatory agent (IL-1Ra) to improve tissue response 
to implanted neural electrodes. 
 We hypothesized that an engineered protease-degradable PEG-maleimide coating 
with incorporated anti-inflammatory agent (IL-1Ra) would improve tissue response to 
implanted electrodes in the brain. We successfully coated the electrode surface with the 
PEG-maleimide coating which showed reduced cell adhesion and cytokine secretion in 
vitro. Additionally, results from an in vivo study indicate neuroprotective effects of the 
IL-1Ra. Gene expression results indicate higher levels of IL-6 and MMP-2 in PEG + IL-
1Ra samples, as well as higher CNTF expression, which is an important marker for 
neuronal survival. 
Project Significance 
 The research completed for this thesis is significant because it contributes to the 
development of coatings for neural implants for enhanced tissue integration. We have 
shown that cell adhesion-resistant polymer coatings alone are not sufficient to reduce scar 
formation and/or inflammation in the brain. However, by adding an anti-inflammatory 
agent we enhanced neuronal survival in the vicinity of the implant. This is an important 
finding because survival of the neurons at the implant interface is necessary for the 
neurons to send signals and maintain electrode functionality. Collectively, these results 






Neural electrodes are important devices for use in systems that can monitor brain 
activity and provide a route of communication between the brain and the rest of the body 
for patients with various medical conditions that limit communication with the nervous 
system. Electrodes are an essential point of contact as they provide the interface between 
the brain and advanced systems known as brain-machine interfaces [2-4]. These brain-
machine interfaces can be used to restore functionality to patients with a variety of brain-
to-body communication issues, including spinal cord injury and control of prosthetic 
limbs [5-9]. In the United States alone, there are an estimated 12,400 new cases of spinal 
cord injury every year [10] as well as 2 million patients currently affected by limb loss 
[11]. These statistics indicate a need to develop new technologies to help improve the 
quality of life for patients experiencing limb loss and spinal cord injury. Neural 
electrodes are implanted in the brain tissue to receive signals from surrounding neurons. 
However, the recording ability of the majority of electrodes fails within days or weeks 
after implantation, rendering the current technology inconsistent and unstable. While 
many modifications have been made to improve long-term neural electrode functionality, 
there are still many issues that persist including inflammation, scar formation, and death 
of neurons surrounding the electrode [1, 12]. Current research aims to find solutions for 




Brain Response to Implanted Materials – Chronic Persistence of Electrode 
Implantation of a foreign material into the body will evoke an immediate response 
by the surrounding tissue which has been well characterized and includes an acute 
inflammatory response, chronic inflammatory response, and formation of granulation 
tissue over time [13]. This foreign body reaction is noted in other types of biosensors as 
well, such as implantable glucose monitoring sensors [14]. Implantation of materials, 
including electrodes, into the brain will elicit a similar response that has been 
characterized in multiple studies and includes acute and chronic inflammation, 
recruitment of microglia and astrocytes, astrocytic scar formation, and death of neurons at 
the implant interface [15-17].  
Upon implantation of an electrode, a cascade of events begins in response to the 
implant. Implantation procedures generally try to avoid large vasculature when inserting 
the electrode, but it is inevitable that some microvasculature will be broken and the blood 
brain barrier (BBB) will be breached. The severity of BBB breach is an important 
determinant in the long-term tissue response to implanted devices, with BBB breach 
causing increased inflammation and neuronal death as well as decreased electrode 
recording functionality [18]. The inflammatory cascade begins with recruitment of 
microglia to the insertion location. Microglia are the macrophages of the brain, and they 
normally exist throughout the brain in a resting state with morphology that resembles a 
star. Upon initiation of the inflammatory cascade, the microglia are sent into an active 
state which causes their morphology to change to a more compact and rounded form [15, 
19, 20]. Both resident and activated microglia are recruited to the site of injury. As the 
electrode persists, the inflammatory cascade continues with further macrophage 
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recruitment as well as astrocyte recruitment [21]. This response is similar to the response 
observed in the rest of the body when monocytes and macrophages are recruited to the 
implant / injury site [13, 22], with the main difference being that microglia, or brain 
specific macrophages, are recruited to the electrode surface.  Astrocytes that are recruited 
to the implant surface then form a physical barrier around the device [23-25], similar to 
the fibrotic capsule the forms around implanted materials in the rest of the body [26]. 
This physical barrier formed by the astrocytes is problematic because it prevents 
electrical signals, sent by surrounding neurons, from reaching the implant surface. If the 
electrical signals cannot reach the electrode surface, the electrode cannot then receive and 
transmit those signals to an external signal processor, essentially rendering the implant 
useless. The inflammatory cascade continues with further macrophage recruitment and 
cytokine release in the surrounding tissue. Figure 2.1 demonstrates the tissue response to 
chronically implanted electrodes as illustrated by Szarowski et al [1]. 
  
Finally, there is neuronal death around the implant itself. The degeneration and 
death of neurons are known side effects of electrode implantation, however the 
mechanisms for neuronal death are not well understood. Cytokines released as a result of 
Figure 2.1: Tissue Response to Chronically Implanted Neural Electrodes [1]. 
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inflammation can lead to downstream neuronal death or survival depending on the 
combination and levels of cytokines that are present [19, 27]. There is also evidence to 
indicate that reducing reactive oxygen species can modulate neurodegeneration [28]. It is 
likely that neuronal death and degeneration are due to a combination of the presence of 
the astrocytic scar, activation of microglia, and the inflammatory cytokines that are 
present in the tissue [29]. 
There are several interesting aspects to the tissue response as it relates to 
implanted neural electrodes. First, the electrode must persist in the tissue in order for the 
inflammatory response to persist. If the electrode is inserted and removed, the tissue will 
eventually mostly heal. Another intriguing observation is the multi-phasic nature of the 
inflammatory response to electrode implantation with persistent placement of electrodes 
as well as stab wounds in the brain. When the electrode is implanted, there is an initial 
inflammatory response that will peak around 2 weeks, decrease, and then increase again 
between 8-16 weeks [30], indicating that the inflammatory response changes over time. 
Finally, there are some differences in the time course when comparing tissue response 
between rat and mouse models with regards to electrode implantation [31], which is an 
important finding as it indicates differences in brain tissue response between species. 
Review of Electrode Technology 
 The tissue response to implanted neural electrodes is similar to the way the body 
responds to various implanted materials, but with unique aspects that are specific to the 
brain. As with all implanted devices, the tissue response to implanted electrodes is 
complex. Many groups have tried to modulate this response through a wide range of 
approaches including designing different electrode geometries, modifying insertion 
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techniques, and applying various coatings to improve the tissue response with varying 
levels of success [16] as described in the following sections. 
Recording Lifetime 
 One of the most significant problems with existing electrode technology is the 
failure of electrode recording over time. In some cases, the cause of the failure is known 
such as broken components within the electrode itself. However, often it is hard to 
pinpoint the exact cause of electrode recording failure. It is believed to be caused by 
some combination of the three major factors discussed previously: glial scar formation, 
inflammation, and neuronal cell death. It is also important to note that electrode failure is 
highly variable. This variability can be due to the type of electrode being used, but it is 
also observed in different animals implanted with the same type of electrode, indicating 
high variability from subject to subject. The recording time line varies among studies, 
with some groups able to record for a year, while other studies show electrode failure 
within a few weeks [32-36]. It is also interesting that some electrodes seem to “recover” 
functionality after initial loss within the first few days or weeks of a study. Occasionally 
electrodes will receive signals for a short time, cease functioning, and regain function 
later. The period of functionality for the second time also varies from study to study. The 
cause of this behavior is unknown but it is possible that the variable inflammatory profile 
plays a role [18, 33]. After initial implantation, the electrode can record for a time until 
inflammation increases. Once the injury reaches a state of stability, the inflammation may 




Electrode Design and Insertion Techniques 
 Many electrode designs have been developed over the last several decades. These 
include Michigan electrodes, Utah arrays, microwires, and polymer electrodes. Examples 
of some of these electrodes can be seen in Figure 2.2 [37, 38]. 
 
Figure 2.2: Examples of Neural Electrode Designs. Left: Utah array; middle: Michigan 
arrays; right: flexible polyimide array 
 
There have been many attempts to improve electrode performance by modifying the 
design or insertion techniques of electrodes to improve one or more aspects of their 
geometry and/or tethering to the skull. First, geometry of the electrodes as well as the 
methods used to insert them can have an effect on the tissue response to the implant [16, 
39]. Mechanical insertion using an assistive device yields better electrode functionality 
than manually inserted electrodes [40]. Bjornsson et al investigated different insertion 
speeds and electrode shapes and determined that the least amount of damage occurred 
with sharp electrodes, inserted at a fast speed, while avoiding all vasculature in the 
surrounding implant site [41]. Edell et al looked at different tip geometries and also found 
that sharp tips caused less tissue trauma upon insertion into the brain [42]. Another 
interesting aspect of electrode design is the geometry of the surface itself. Ereifej et al 
analyzed multiple surfaces and found that a nano-patterned electrode surface with 
specified geometry (3600 grooves/mm, 277 nm wide) had less protein adsorption, cell 
 9 
adhesion, and cell proliferation than other surfaces tested [43]. As one might expect, 
smaller electrodes evoke a reduced inflammatory response compared to larger electrodes 
[34]. Kozai et al. showed the effectiveness of a microthread electrode to maintain 
recording function while minimizing blood-brain-barrier disruption as well as reducing 
tissue response compared to silicon electrodes, with reduced astrocyte and microglial 
recruitment [34].   
 Another important aspect of electrode design involves whether or not the 
electrode is tethered to the skull [33, 44]. After implantation, it is necessary to keep the 
electrode firmly implanted in the brain such that it does not move around or fall out of the 
brain as the animal moves. Some electrode designs utilize an “untethered” design 
meaning that the entire electrode apparatus is attached to the skull as one piece, usually 
with an acrylic material that hardens upon application. Other electrodes utilize a 
“floating” design where the implanted portion is placed in the brain similar to the 
untethered design, but the electrode itself contains an additional wire between the 
electrode and the external connector. This external connector is also attached to the skull 
with an acrylic headcap, but since the connector is not directly in line with the electrode, 
in has the ability to move freely from the electrode, minimizing micromotion that occurs 
as the animal moves.  
One of the most complete studies to date by Karumbaiah et al. analyzed the 
differences between multiple electrode designs and tethered vs. untethered probes [33]. 
Comparing the histological response, cytokine release, and electrode recording 
performance among different electrode designs indicated that there is not one particular 
electrode design that solves all problems. While one electrode design might perform 
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better in one area, another design would outperform in another. An additional 
consideration of electrode design must be the potential blood-brain barrier breach. Saxena 
et al. conducted a thorough study of BBB breach and observed that electrodes causing a 
larger BBB breach also had an increased inflammatory response as well as a higher 
probability of electrode failure over time [18]. In addition, there was also variability 
among microwire electrodes with the same electrode design, indicating that electrode 
response is non-uniform even when using the same design. Collectively, these results 
indicate that electrode design alone may not be enough to mediate the tissue response and 
maintain long-term electrode functionality.  
Electrode Materials and Coatings 
 Electrodes can be made of many materials including silicon, tungsten, other 
metals, ceramics, and a range of electrically active polymers like polyimide and parylene 
[16, 45, 46]. Silicon, tungsten, and ceramics are hard, non-compliant materials that 
possess a mechanical mismatch from the relatively soft tissue of the brain. New research 
with more compliant materials has shown improvements in tissue response surrounding 
the electrode [47]. Polymer microelectrode arrays that are less stiff than “traditional” 
electrode materials have shown mechanical compliance as well as necessary electrical 
performance [48]. A modified poly(vinyl acetate) electrode that more closely matches the 
mechanical stiffness of the brain showed promising results in being able to withstand the 
forces necessary to implant in the brain while also yielding increased neuronal survival 
around the implant [49, 50]. 
Research groups have applied various coatings to the surface of electrodes in an 
attempt to improve electrode performance as well as the in vitro and in vivo response to 
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electrodes. Conductive coatings are a widely-tested option as they can improve the 
electrical performance of the electrode. Combinations of poly(3,4-
ethylenedioxythiophene) / poly(styrene sulfonate) (PEDOT/PSS) or polypyrrole (PPy) 
with a peptide-derivative from laminin have shown promising results to decrease 
impedance on the active sites of electrodes, making it easier for neuronal signals to reach 
the electrode surface [51-53]. However, there are concerns about long-term stability of 
such coatings in vivo as well as questions about the ability to effectively incorporate 
bioactive factors into these electrically active polymers [54].  
In addition to electrically active polymers, others have tried passive polymer 
coatings to reduce protein adsorption and cell adhesion on the electrode surface. Azemi et 
al. coated silicon electrodes with a layer of laminin and seeded neural progenitor cells 
before implantation for a seven day study which showed reduced astrocytic scar 
formation compared to unmodified electrodes [55]. Polyaniline-coated platinum 
electrodes [56] and low-protein binding polymer films on silicon electrodes [57] showed 
reduced protein adsorption in vitro compared to unmodified controls. Poly(vinyl alcohol) 
/poly(acrylic acid) coatings also showed reduced protein adsorption and reduced 
astrocyte recruitment around the electrode site [58], while combination 
PEG/polyurethane coatings have shown reduced glial scarring and neuronal death around 
PEG/PU coated electrodes [59]. Conversely, a study with Parylene-C coated electrodes 
showed no difference in glial markers or neuronal survival compared to uncoated 
electrodes [60], indicating that non-fouling coatings alone may not provide enough 
intervention to solve the problems with chronically implanted neural electrodes.  
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Drug and Immunomodulatory Agent Delivery 
Whereas polymer coatings may yield some improvements in tissue response, it 
may also be necessary to incorporate bioactive factors into neural electrode coatings. 
There have been multiple studies that have attempted to modify the tissue response using 
a range of drugs and immunomodulators as there is evidence to suggest that controlled 
release of anti-inflammatory agents can mediate the long-term tissue response to 
implanted biomaterials [61]. Bezuidenhout et al. demonstrated the effectiveness of 
loading dexamethasone into degradable and non-degradable PEG hydrogels to improve 
tissue response [62]. Further studies showed reduced inflammatory response and 
increased neuronal survival with dexamethasone-releasing coatings [63-67]. Tethering α-
melanocyte stimulating hormone onto the surface of an electrode attenuated 
inflammatory cytokine release in vitro [68]. Incorporation of TGF-β on a laminin coating 
yielded reduced astrocytic recruitment on the electrode surface compared to laminin 
alone, indicating a potential target for reducing astrocytic scar formation [69]. Several 
groups have also investigated multi-function coating approaches that attempt to solve 
several problems simultaneously. Abidian and Martin demonstrated the ability to 
incorporate slow-release dexamethasone into an alginate hydrogel with PEDOT 
functionalization to improve electrical impedance with promising release characteristics 
in vitro [70], while Wadhwa et al. showed similar results with a polypyrrole coating and 
dex release in vitro [71]. Potter et al. utilized a poly(vinyl alcohol) material to improve 
the mechanical characteristics of the electrode to reduce mechanical mismatch while also 
incorporating curcumin to mediate the inflammatory response [72] with promising results 
at 4 weeks post-implantation, but all improvements were lost by 12 weeks.  
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In addition to drug therapeutics, it is also possible to target individual cytokines 
that are involved with inflammation in the brain. There are many cytokines involved in 
brain injury, disease, and inflammation. The cytokines responsible for modulating 
microglial activity and the inflammatory cascade in the brain include IL-1α, IL-1β, IL-
1Ra, IL-4, IL-6, IL-10, IL-18, TNF-α, M-CSF, MIP-1α, MIP-1β, MIP-2 [19, 73-79]. 
With all of the cytokines that have been identified to have an effect on the inflammatory 
cascade in the brain, it is apparent that the tissue response to implanted electrodes is a 
complex problem that cannot be solved with polymer coatings alone, and an 
immunomodulator is likely necessary to improve the long-term functionality of implanted 
electrodes. Interleukin 1 (IL-1) is an important cytokine in the inflammatory cascade both 
in the brain and throughout the body, and presence of IL-1 can promote production of 
additional cytokines in the inflammatory cascade. IL-1 includes two agonists, IL-1α and 
IL-1β, both of which are 17 kDa molecules. These molecules are found in many 
inflammatory diseases and conditions within the body including inflammatory bowel 
disease, cancer, arthritis, arterial disease, kidney disease, and osteoporosis among others 
[73, 80]. Interleukin-1 receptor antagonist (IL-1Ra) is a 17 kDa protein that has been 
implicated as an important mediator of inflammation in diseases and conditions that 
contain IL-1 as part of the inflammatory cascade [73, 80]. IL-1Ra is the receptor 
antagonist for IL-1, meaning that the IL-1Ra molecule competes to bind IL-1 receptors in 
the cell. In the central nervous system, IL-1Ra has been shown to be effective in reducing 
inflammation in other CNS injury models such as the spinal cord, and it is also implicated 
in the recovery process after brain ischemia as well as stroke [73, 80]. IL-1Ra has also 
been shown to have neuroprotective effects when released by microglia [81]. Taub et al. 
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examined the effects of IL-1Ra integrated into a laminin coating on neural electrodes and 
noted moderate improvement of the astrocyte response to the IL-1Ra coated electrodes 
compared to uncoated controls, however no other cell types were analyzed [82]. 
Additionally, IL-1Ra is already approved for use in humans as a therapeutic for other 
inflammatory conditions such as arthritis [80]. Based on all this data, we hypothesized 
that IL-1Ra is a suitable candidate as an immunomodulator to improve the tissue 
response to implanted neural electrodes.  
MMP-degradable Coatings 
Matrix metalloproteinases (MMPs) are present in many tissues throughout the 
body and play an important role in tissue homeostasis and extracellular matrix 
remodeling. In addition to cell and tissue maintenance, MMPs are up-regulated in many 
disease states and conditions that cause increased inflammatory response [83, 84] 
including neurodegenerative diseases [85], central nervous system injury [86-88], and 
brain injury [89, 90].  MMPs are also necessary for mediation of inflammation, as MMP-
9 deficiency has been shown to prolong the foreign body response in the brain [91]. With 
regards to electrode implantation, MMP-2 and MMP-9 have been implicated in the 
inflammatory cascade that occurs in response to neural electrodes [18, 76], indicating that 
the presence of MMPs in the injured brain does play a role in the chronic tissue response.  
Since MMPs are up-regulated in the inflammatory cascade in the brain, it is 
possible to utilize MMPs that are already present in the inflamed tissue to serve as the 
stimuli to break down a material, such as a hydrogel, that contains MMP-degradable 
motifs. The use of MMP-degradable hydrogels has been demonstrated by several groups. 
These MMP-degradable hydrogels have been shown to be effective for a range of uses 
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including encapsulation of mesenchymal stem cells [92], fibroblasts [93, 94], vascular 
smooth muscle cells [95], drugs [96], and biomolecules such as RGD and VEGF [97-99].  
The MMP-degradable nature of these hydrogels allows for the cells to remodel the gels, 
allowing for cell ingrowth as well as release of any incorporated bioactive factors. By 
incorporating anti-inflammatory drugs into these hydrogels, it is possible to take 
advantage of the inflammatory nature of an injury model, such as the implanted 
electrode, to utilize the existing MMPs in the tissue as the stimulus for cleaving the 
MMP-degradable motifs to release tethered anti-inflammatory molecules. An added 
benefit of this system is the on-demand release aspect as the MMP-degradable sequences 
are degraded in the presence of the MMPs that occur during inflammation. A system with 
this on-demand release of bioactive factors could be useful for mediating inflammatory 
response when used in conjunction with implanted biomaterials to improve implant 
biocompatibility. 
Conclusion 
 Brain-machine interfaces have the potential to provide real change in improving 
the quality of life for patients with various life-altering conditions including limb loss and 
spinal cord injury. However, the electrodes that are used to interface with the brain still 
have limitations that must be addressed to maintain long-term electrode functionality. 
There has been much research into probe design, insertion techniques, tethering to the 
skull, in addition to a wide range of coatings to reduce cell adhesion, improve electrical 
impedance, improve neuronal survival, and reduce the inflammatory response. However, 
no single approach has been able to completely address all aspects of the tissue response 
to modulate inflammation, yield reduced cell recruitment and scarring, and maintain 
 16 
neuronal survival near the implant interface. It is important to investigate other options 





HOST RESPONSE TO MICROGEL COATINGS ON NEURAL 






The performance of neural electrodes implanted in the brain is often limited by 
host response in the surrounding brain tissue, including astrocytic scar formation, 
neuronal cell death, and inflammation around the implant. We applied conformal 
microgel coatings to silicon neural electrodes and examined host responses to microgel-
coated and uncoated electrodes following implantation in the rat brain. In vitro analyses 
demonstrated significantly reduced astrocyte and microglia adhesion to microgel-coated 
electrodes compared to uncoated controls. Microgel-coated and uncoated electrodes were 
implanted in the rat brain cortex and the extent of activated microglia and astrocytes as 
well as neuron density around the implant were evaluated at 1, 4, and 24 weeks post-
implantation. Microgel coatings reduced astrocytic recruitment around the implant at 
later time points. However, microglial response indicated persistence of inflammation in 
the area around the electrode. Neuronal density around the implanted electrodes was also 
lower for both implant groups compared to the uninjured control. These results 




 adapted from: 
Stacie M. Gutowski, Kellie L. Templeman, Antoinette B. South, Jeffrey C. Gaulding, 
James T. Shoemaker, Michelle C. LaPlaca, Ravi V. Bellamkonda, L. Andrew Lyon, 
Andrés J. García. Host response to microgel coatings on neural electrodes implanted in the 
brain. J Biomed Mater Res Part A: 102A: 1486–1499, 2014. 
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demonstrate that microgel coatings do not significantly improve host responses to 




Neuroprosthetic devices have the potential to restore functionality to patients 
affected by injuries and pathologies including sensory loss, neurological disorders, spinal 
cord injuries, and limb amputation [4-6, 8]. Devices that provide an interface between 
brain and machine require the use of neural electrodes that can receive and/or transmit 
electrical signals from neurons in the brain [4-6, 8]. A significant problem with current 
electrode technology is recording failure of electrodes over time. Devices implanted in 
the body provoke an inflammatory response from the surrounding tissue, which can lead 
to scar formation and failure of the implant over time [13]. Electrode failure involves host 
responses in the tissue surrounding the electrode including increased glial scar formation 
and a decrease in neurons due to cell death around the electrode [1, 25, 66]. Additionally, 
activation of microglia around implanted electrodes supports a role for inflammation in 
the tissue response around the implant [1]. Maintenance of recording ability varies from 
days to many months, however the time frame of electrode functionality is highly 
variable even between electrodes in the same array and many electrodes can fail within a 
matter of weeks after implantation [4].  In order to improve long-term electrode 
functionality, it is important to introduce a device that will elicit minimal reaction from 
the surrounding tissue [15]. By incorporating materials that reduce astrocytic and 
microglial cell adhesion, it may be possible to reduce scar formation around implanted 
materials.  
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To improve the tissue response to implanted neural electrodes, several groups 
have applied coatings to the electrode surface as a potential solution. Coatings with an 
incorporated peptide sequence derived from laminin promote neuronal cell adhesion and 
migration [51, 53, 55], as well as coatings containing brain-derived neurotrophic factor 
[100]. Whereas these coatings may increase neuronal cell numbers around the electrode, 
they may also promote adhesion of other cell types including astrocytes, one of the main 
cell types involved in scar formation. Recent work by Winslow et al. [60] demonstrated a 
lack of improved tissue response with cell adhesion resistant coatings, indicating the 
possible role of persistent inflammation in the long-term tissue response that results in 
electrode failure. Other studies have investigated releasing anti-inflammatory agents 
including α-melanocyte stimulating hormone [68] and dexamethasone [64, 65, 67] to 
attenuate the inflammatory response of surrounding tissue. While this research has 
introduced many improvements to the field, there has been limited success in improving 
long-term cellular response as a whole for time points longer than several weeks, and 
much work remains to mediate the problems involved with chronically implanted 
electrode failure.  
In the present study, we engineered a conformal microgel coating to reduce cell 
adhesion on neural electrodes. This coating consists of multi-layers of cross-linked 
microgel particles composed mainly of poly(N-isopropylacrylamide) (pNIPAm), which is 
cross-linked with poly(ethylene glycol diacrylate) (PEG-DA). Under physiological 
conditions, the PEG chains decorate the surface of the pNIPAm microgels, serving as a 
non-fouling coating that has been shown to reduce protein adsorption and cell adhesion, 
as well as reduce inflammation in vivo [101-103]. The microgel coating is tethered to the 
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surface of silicon electrodes which are manufactured for neural recording applications 
[32]. We evaluated in vitro cell adhesion and host responses to microgel-coated and 
uncoated electrodes implanted in the rat brain. Our results in combination with previous 
studies indicate the need for materials that go beyond reducing cell adhesion alone but 
also incorporate improved attenuation of inflammation in the tissue surrounding the 
implanted electrode. 
Materials and Methods 
 
Microgel coating of electrodes 
The electrode modifier used for this study is a thermo-responsive, micro-
structured, hydrogel coating. This coating consists of multilayers of particles of 
copolymer poly(N-isopropylacrylamide) (pNIPAM) and acrylic acid (AAc) (pNIPAm-
coAAc) cross-linked with poly(ethylene glycol) (PEG) chains. Particle size and 
composition were previously verified by dynamic light scattering and NMR, respectively 
[103]. Microgel coatings were applied to the surface of electrodes made of silicon and 
iridium. Electrodes were purchased from NeuroNexus Technologies (CM16 A4x4-4mm-
200-200-1250). Each electrode is 4 mm long with 4 active sites on each of 4 prongs, and 
each active site has an area of 1,250 µm
2
. Non-recording electrodes were used as they are 
significantly less expensive than functional electrodes.  
Preliminary studies indicated variable application of coatings due to organic 
contaminants on the as-received electrode surface. Several cleaning protocols were 
evaluated by surface analyses and reproducible application of coating. An optimal 
cleaning procedure consisting of serial 5-minute incubations in trichloroethylene 
(Mallinckrodt/JT Baker), acetone (Sigma-Aldrich), and methanol (Sigma-Aldrich) was 
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used. Electrodes were then rinsed with absolute ethanol (Sigma-Aldrich). Following the 
cleaning procedure, electrodes were incubated in absolute ethanol for one hour. The 
surface was functionalized using a silane-based adhesion layer. Silicon has a natural 
oxide layer approximately 1 nm thick, and this layer was utilized for silanization of the 
surface. The electrodes were incubated for two hours with 1% 3-aminopropyl 
trimethoxysilane (APTMS, TCI America) in absolute ethanol. The substrate was then 
rinsed with ethanol and equilibrated in PBS. Anionic microgels were then added and 
Coulombic attraction between the cationic amine-modified silicon surface and anionic 
microgels resulted in the formation of a microgel monolayer. To further stabilize the 
initial layer, chemicals for carbodiimide coupling were used consisting of N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), N-
hydroxysuccinimide (NHS), and hydroxylamine hydrochloride. Standard EDC/NHS 
coupling was used [104] to covalently attach the microgels to the silicon surface. 
Complete coverage of the surface with microgels was achieved by depositing four layers 
of microgels to coat the electrode surface. A cationic glue, polydiallyl dimethyl 
ammonium chloride (PDADMAC), was used between layers to promote multi-layer 
formation. Presence of the microgel coating was verified with atomic force microscopy 
(AFM) and X-ray photoelectron spectroscopy (XPS) (Fig.1). Upon completion of 
coating, or after cleaning for uncoated samples, electrodes were placed in PBS until 





In Vitro Cell Adhesion 
 Either uncoated or microgel-coated electrodes were adhered to a glass coverslip 
using UV-cure adhesive (NOA 68, Norland Adhesives). A single coverslip with attached 
electrode sample was placed in an individual well of a 12-well plate (n=3, each group). 
The samples were washed twice with 70% ethanol followed by three washes with sterile 
PBS. Mixed astrocyte and microglial cells were added to each well at a density of 50,000 
cells/cm
2
 (~190,000 cells/well). The samples were cultured in DMEM/F12 (Invitrogen) + 
10% FBS (Invitrogen) at 37 ºC and 5% CO2 for 24 hours. Samples were stained with 
LIVE/DEAD stain (Invitrogen) and imaged with a 20X Apo Nikon objective (0.75 NA). 
Cell spread area on the electrode surface was measured using ImageJ software (NIH).   
Electrode Implantation 
NIH guidelines for the care and use of laboratory animals (NIH Publication #85-
23 Rev. 1985) were observed. All surgical procedures were approved by the Institutional 
Animal Care and Use Committee at the Georgia Institute of Technology. The electrode 
implantation procedure is adapted from the protocol by McConnell et al. [17] Electrodes 
(uncoated, microgel-coated) were rinsed with ethanol for 24 hours then washed with 
sterile PBS prior to implantation in the brain cortex of a rat, one per animal (n=4 animals 
for all groups except n=3 for uncoated at 24 weeks, similar sample sizes were used in 
other studies [24, 30, 105]). Male Sprague-Dawley rats (Charles River Laboratories) were 
anesthetized with isoflurane. The surgical site was shaved, cleaned with chlorohexaderm, 
and rinsed with isopropyl alcohol before mounting the animal onto a stereotactic frame. 
Marcaine (0.15 mL of 0.5%) was injected subcutaneously at the site of incision. A 
midline incision 2-3 cm long was made in the scalp and the periosteum retracted to 
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expose the cranium. Five 1 mm-diameter pilot holes were made around the skull, four 
posterior to bregma, with two each on either side of the midline and one additional hole 
made anterior and right of bregma. A 4.7 mm stainless steel bone screw (Fine Science 
Tools 19010-00) was inserted into each of the pilot holes, with each screw penetrating the 
skull but leaving about 1-2 mm of each screw head remaining out of the skull to serve as 
an attachment point for the headcap. The craniotomy for electrode insertion was made 
anterior to and left of bregma using a 2.7 mm trephine bit (Fine Science Tools 18004-27). 
The electrode was held in the stereotactic frame above the 2.7 mm hole and slowly 
lowered into the cortex, careful to avoid any large vasculature in the surgical area. 
Agarose gel (1.5% w/v, SeaKem) was filled into the opening around the electrode and 
dental acrylic (OrthoJet, Inc.) was used to anchor the electrode assembly to the skull. The 
scalp incision was closed via wound clips and triple-antibiotic ointment was applied to 
the wound. Each animal was given an injection of 5 mL saline and allowed to recover 
from anesthesia before receiving a 0.03 mg/kg buprenorphine injection for pain relief. All 
animals were fully ambulatory post recovery. 
 At the designated time point (1, 4, and 24 weeks), the animal was anesthetized 
prior to transcardial perfusion with 200 mL 0.4% papaverine HCl in 0.9% NaCl, followed 
by 50 mL of 0.9% NaCl, and 200 mL of 4% paraformaldehyde in phosphate buffer. After 
perfusion, the skull was opened and the brain retrieved from the skull cavity. All samples 
were kept in 4% paraformaldehyde in phosphate buffer solution overnight then placed in 
30% sucrose in PBS until the brain sank to the bottom of a 50 mL conical tube. Samples 




 Samples were sectioned in 16 µm-thick sections using a cryostat and stained for 
various cell markers as indicated in Error! Reference source not found.. All primary 
antibodies were visualized with AlexaFluor488-conjugated secondary antibody 
(Invitrogen) and counterstained with DAPI for cell nuclei recognition. Upon completion 
of staining, all slides were imaged using a 10X Nikon objective (0.30 NA) and SPOT 
Advanced software (Diagnostic Instruments, Inc.). 
Table 3.1: Antibodies used for immunofluorescence analysis 
 
Data obtained from in vivo studies were analyzed using MATLAB software 
(Mathworks). A line was drawn manually along the edge of the injury caused by the 
electrode and the intensity values were gathered starting at the edge of the injury and 
moving 500 μm perpendicularly from the line (Fig. 3.3a) [12]. For GFAP, ED1, and 
OX42 staining, the average intensity was normalized to the intensity of the contralateral 
[background] image by utilizing point by point subtraction of the background staining 
(obtained from the corresponding contralateral uninjured hemisphere) from the injury 
image, taking into account the variation of field illumination. This method allows for 
subtracting the uninjured tissue staining of resident cells (GFAP and OX42), subtraction 
of the background (ED1), and accounting for the variation in field illumination in all 
samples. The normalized intensity per trajectory was plotted, yielding a curve indicating 
the intensity variation as a function of distance (x) from the edge of the implanted 
Antibody Supplier Cell Type 
Glial fibrillary acidic protein (GFAP) Abcam ab7260 Astrocytes 
NeuN Millipore MAB377 Neuronal nuclei 
OX42 / CD11b Chemicon CBL1512 Resident microglia 
ED1 / CD68 AbD Serotec MCA341R Activated microglia 
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electrode (Fig. 3.3a, right). Each curve was fit to equation 1 and a five-parameter fit 
applied to each curve.  








+ f.  
This equation was chosen for the curve fit because there are two intensity and 
decay parameters in the equation corresponding to the initial steep decay in the intensity 
at distances corresponding to 0–100 µm (parameters: intensity1 and decay1) followed by a 
slower rate of decay at distances >100 μm from the edge of injury (parameters: intensity2 
and decay2). Samples from each animal were used to generate independent intensity 
curves for each marker (GFAP, OX42/CD11b, ED1/CD68). The intensity curves for each 
individual animal were then combined and analyzed to obtain an inter-animal average per 
group for each marker at each time point. Analysis for NeuN staining utilized a similar 
methodology by analyzing cell staining starting at the scar and moving 500 µm away 
from the injury. However, staining is analyzed by counting NeuN+ cells [12] per 100 µm 
bin (Fig. 3b), as the staining for NeuN is either positive or negative for neuronal nuclei, 
with the number of positive cells indicating the number of neuronal nuclei in the analysis 
area. The number of NeuN+ cells is then plotted as a percentage of the corresponding 
uninjured control (contralateral hemisphere) (Fig 3b, bottom). Samples from each animal 
were combined to obtain an inter-animal average per group for NeuN at each time point. 
Statistical Analysis 
Data presented are mean +/- standard error. Statistical analyses for differences in 
the in vitro cell adhesion study were performed using a two-tailed t-test in JMP Pro10 
(SAS Software). Mean and standard error for parameters of curve fits from non-linear 
regression (intensity1, intensity2, decay1, decay2) for GFAP, OX42, and ED1 for uncoated 
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and microgel-coated samples were obtained using the two-phase decay equation 
(Equation 1) in Graphpad Prism 6.0. Statistical analyses for differences between the two 
groups at a given time point were performed using a t-test. Analysis for differences in 
each parameter over time were performed using ANOVA with post-hoc analysis (Tukey) 
for comparison at different time points. Staining for NeuN+ cells was analyzed per 100 
µm bin and compared between uncoated samples, microgel-coated samples, and 
contralateral uninjured controls using ANOVA in JMP Pro10 (SAS Software). Post-hoc 
testing consisted of Dunnett’s method to test for differences between the contralateral 
(uninjured control) and experimental (uncoated and microgel-coated) samples, and 
Tukey-Kramer HSD test was used to test for differences between uncoated and microgel-
coated samples in each bin per time point. A p-value of <0.05 was considered significant. 
Results 
 
Characterization of Microgel Coatings 
Microgel coatings were characterized using atomic force microscopy (AFM) and 
X-ray photoelectron spectroscopy (XPS) to validate morphology and chemical 
composition. Figure 3.1a shows the molecular structure of the microgels consisting of N-
isopropylacrylamide (NIPAm; 70.5 mol%), acrylic acid (AAc; 26 mol%), and the 
crosslinker poly(ethylene glycol) diacrylate (MW=575, PEGDA-575; 3.5 mol%). AFM 
analysis of electrodes that were cleaned, incubated with only APTMS and PDADMAC, 
and microgel-coated indicated a uniform conformal coating of microgels on the surface 
of the microgel-coated electrode (Figure 3.1b). The microgel coating covered both the 
silicon substrate as well as the iridium wire that is used for transmission of the electrical 
signal. As this study only utilized non-recording electrodes for the purposes of 
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histological evaluation, no tests were performed to observe changes in impedance at the 
electrode recording sites. However, because of the high water content of these films 
(~90%), we do not expect significant changes in the electrical impedance of the device. 
AFM analysis to determine wet thickness of the microgel coating was performed by 
introducing a scratch into the coating with a razor blade, exposing the bare substrate next 
to the microgel-coated area, and measuring the thickness of the coating in relation to the 
bare substrate. This analysis indicated microgel coating thickness of ~60 nm, which is 
consistent with previous studies [106]. Figure 3.1c indicates the change in chemical 
composition of the surface as analyzed by XPS. The presence of Si peaks is likely due to 
collapse of the microgel coating under vacuum within the penetration depth of the 
technique. Note the change in XPS spectra indicating increased carbon and nitrogen 
peaks on the microgel-coated electrodes corresponding to deposition of a coating on the 
electrode surface. Taken together, the AFM and XPS results demonstrate application of a 







Figure 3.1: Microgel coatings applied to the surface of the neural electrode. (a) Chemical structure of 
the microgel contains pNIPAm, PEG, and acrylic acid. (b) Photo of the neural electrode (left) with AFM 
scans for uncoated, PDADMAC+APTMS only, and multi-layer microgel-coated surfaces. The microgel 
coating application was further verified using X-ray electron spectroscopy to verify differences between 
the uncoated and microgel-coated (c) surfaces with the absence of iridium 4f peak and prominent C1s 
and N1s peaks on the microgel-coated sample.  
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In Vitro Cell Adhesion  
Uncoated and microgel-coated electrodes were seeded with mixed glial cells 
(astrocytes + microglia) to evaluate adhesion to these materials. Analysis of results from 
the in vitro experiment indicates the effectiveness of the microgel coating for reducing 
cell adhesion on the surface of electrodes as well as high viability (>99%) of plated cells. 
Similar cell density and cell spreading were observed on the glass coverslip beneath each 
sample, indicating continuity of cell seeding and spreading between samples (Figure 
3.2a). There was significantly reduced cell adhesion and cell spreading on the microgel-
coated electrode surface as compared to the uncoated control (Fig. 3.2b). Each of these 
representative images shows significantly higher cell adhesion and spreading on the 
uncoated electrodes whereas the microgel-coated images indicate very few cells attached 
to the surface and reduced cell spreading.  The total cell spreading was analyzed by 
taking a series of images along the length of the electrode and averaging total cell spread 
area per electrode. Cell spread area was quantified (Fig. 3.2c) by determining the area of 
the cells present on the electrode surface using ImageJ area measurement tool. There was 
a significant difference in cell spread area between the samples, with approximately 60 







Figure 3.2: Electrodes were plated with mixed glial cells (astrocytes and microglia) and cultured for 
24 hours. (a) Representative images of the in vitro assay showing cell adhesion on the uncoated (left) 
and microgel-coated (right) electrodes and underlying coverslips, indicating continuity of cell density 
and cell spreading on the coverslip beneath each electrode. (b) Microgel coatings reduce in vitro 
mixed glial cell adhesion on electrodes. Samples were stained using LIVE/DEAD stain (Invitrogen) 
and imaged using fluorescence microscopy. (c) Cell spreading area was analyzed using ImageJ to 
determine the amount of cell spread area for each group. Microgel coatings reduced cell adhesion on 
the electrode surface compared to uncoated controls (p<0.01).  Data is presented as mean ± standard 
error of the mean, n=3 electrodes. Scale bars = 100µm.  
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Host Response of Electrodes Implanted in the Brain 
Microgel-coated electrodes and uncoated controls were implanted into the rat 
cortex. Tissue responses in the vicinity of the electrode were analyzed at three time 
points: 1 week, 4 weeks, and 24 weeks using immunostaining of cryosectioned samples. 
Image analysis was implemented to quantify levels of markers associated with 
neuroinflammation and neuronal cell survival (Fig. 3.3). Markers associated with 
neuroinflammation comprised GFAP (astrocytes), OX42/CD11b (resident macrophages), 
and ED1/CD68 (activated macrophages). Each of these markers was used to stain 
sections from all animals. Images from each sample were analyzed and staining 
intensities for each marker over a distance of 500 µm perpendicular from the edge of the 
electrode injury were evaluated. These intensity profiles were then fit using non-linear 
regression to Equation 1. In this equation, the initial set of parameters, intensity1 and 
decay1, correspond to the initial steep descent of the intensity curve and represent the host 
response in area closest to the electrode surface at distances ≤100 µm. The second set of 
parameters, intensity2 and decay2, correspond to the second phase of the curve with 
gradual descent of the intensity, indicating cell response in the area farther from the 
electrode at distances >100 µm.  
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Figure 3.3: Analysis of immunostaining was performed using a custom MATLAB program. (a) The 
IHC images for each sample of GFAP, OX42, or ED1 stained sections were displayed and a curve 
generated along the edge of the scar formed by the electrode. A scale bar (left) indicates the intensity 
values of the staining from 0 (black) to 1 (white). The program determines the average of the 
intensity along the curve from 0-500µm away from the scar and generates an intensity curve as a 
function of distance. Sample intensity curve is shown from an uncoated electrode at 24 weeks for 
GFAP stain (a, right). This curve is fit with Equation 1 and parameters for each curve are compared 
between groups. (b) Image processing for NeuN stained samples involves dividing the 500 µm image 
into 5 equal-sized bins of 100 µm and counting NeuN positive cells in each bin. These NeuN+ cell 




Representative images of immunostaining for GFAP (astrocytes, Fig. 3.4a) show 
the progression of astrocytic scar formation as well as representative intensity curves 
(Fig. 3.4b, Fig. 3.7) at 1 week, 4 weeks, and 24 weeks. Plots of the curve fit parameters 
for intensity (Fig. 3.4c) indicate changes in the parameters over time. At 1 week, the 
microgel-coated samples had higher staining for intensity1, decay1, and intensity2 
parameters while decay2 was lower compared to uncoated electrodes. There were also 
significant increases for intensity1 and decay1 for both uncoated and microgel-coated 
samples from 1 to 4 weeks, while the decay2 parameter decreased for uncoated samples. 
At 4 weeks, staining for intensity1, decay1, and decay2 parameters were higher for 
microgel-coated samples while intensity2 was higher for uncoated samples. From 4 to 24 
weeks intensity1 and decay1 decreased for microgel-coated electrodes. At 24 weeks, all 
parameters were higher for uncoated electrodes than microgel-coated electrodes.  
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Figure 3.4: Immunofluorescence images and corresponding intensity scale (a) from each time point 
and group of samples stained with glial fibrillary acidic protein (GFAP), a marker for astrocytes (n=4 
animals for all groups except n=3 for uncoated at 24 weeks). Curve fits on each intensity curve are 
completed using Equation 1. Representative intensity curves from background-corrected images (b) 
are located below the representative immunostaining images for each time point. Parameter curves 
(c) indicate changes in parameter values over time for the experimental groups. Symbols indicate: * 
significant differences between the groups at one time point, ‡  significant differences over time 
between the indicated and preceding time-point for uncoated samples, #  significant differences over 
time between the indicated and preceding time-point for microgel-coated samples. 
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OX42 staining (resident microglia, Fig. 3.5a) and representative intensity curves 
(Fig. 3.5b, Fig. 3.7) were analyzed in a similar manner to GFAP, with curve fit 
parameters represented in Fig. 3.5c. At 1 week, intensity1 and decay2 were higher for 
uncoated samples while intensity2 and decay1 were higher for microgel-coated samples. 
From 1 to 4 weeks, decay1 increased for microgel-coated samples whereas decay2 
decreased for uncoated electrodes. At 4 weeks, all parameters were higher for microgel-
coated electrodes compared to uncoated controls. From 4 to 24 weeks decay1 decreased 
for microgel-coated samples. At 24 weeks, uncoated samples had higher intensity1 and 
decay1 and lower intensity2 parameter values than microgel-coated samples.  
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Figure 3.5: Immunofluorescence images and corresponding intensity scale (a) from each time point 
and group of samples stained with OX42 (CD11b), a marker for microglia. Representative intensity 
curves from background-corrected images (b) are located below the representative immunostaining 
images for each time point. Parameter curves (c) were generated in a similar manner to those for 
GFAP and indicate changes in intensity and decay values over time for the experimental groups. 
Symbols indicate: * significant differences between the groups at one time point, ‡  significant 
differences over time between the indicated and preceding time-point for uncoated samples, #  




Results for ED1 staining (activated microglia, Fig. 3.6a) and representative 
intensity curves (Fig. 3.6b, Fig. 3.7) indicated the changes in parameters over time (Fig. 
3.6c). At 1 week, intensity1 and intensity2 were higher for uncoated electrodes compared 
to microgel-coated electrodes. From 1 to 4 weeks, decay1 and intensity2 parameters 
decreased for uncoated electrodes while decay1 increased for microgel-coated samples. 
At 4 weeks intensity1, intensity2, and decay2 were all higher for uncoated samples while 
decay1 was lower than that for microgel-coated samples. From 4 to 24 weeks, parameters 
for uncoated electrodes increased for intensity1 and decay1 while decay1 decreased for 
microgel-coated samples. At 24 weeks, intensity1, decay1, and intensity2 were higher and 
decay2 was lower for uncoated electrodes compared to microgel-coated electrodes.  
 38 
Figure 3.6: Immunofluorescence images and corresponding intensity scale (a) from each time point 
and group of samples stained with ED1 (CD68), a marker for activated microglia. Representative 
intensity curves from background-corrected images (b) are located below the representative 
immunostaining images for each time point. Parameter curves (c) were generated in a similar manner 
to those for GFAP and indicate changes in parameter values over time for the experimental groups. 
Symbols indicate: * significant differences between the groups at one time point, ‡ significant 
differences over time between the indicated and preceding time-point for uncoated samples, # 
significant differences over time between the indicated and preceding time-point for microgel-coated 
samples. 
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Figure 3.7: Intensity curves for each time point showing the staining intensity for each individual 
sample using GFAP (top row), OX42 (middle row), and ED1 (bottom row) at 1 week (left column), 4 




Data obtained from NeuN (neuronal nuclei) staining was analyzed such that each 
image was divided into five 100 µm bins, allowing for each NeuN+ cell to be counted 
and normalized to the uninjured contralateral side (Fig. 3.3b). Each image was plotted 
with the first bin starting at the edge of the implant. The number of NeuN+ cells per bin 
were plotted to determine changes in neuronal density for each group. Representative 
images of NeuN staining (Fig. 3.8a) indicated the presence of neuronal nuclei in each 
sample group, as quantified in Fig. 3.8b. At 1 week the uncoated and micorgel-coated 
samples were significantly lower than the contralateral (control) samples at 0-100 µm and 
100-200 µm bins for both groups. At 4 weeks, NeuN+ staining around uncoated samples 
was significantly lower than microgel-coated samples at 0-100 µm, and both groups were 
significantly lower than the contralateral control at the same distance. Additionally, the 
uncoated samples were significantly lower than the contralateral control at 200-300 µm. 
At 24 weeks, the microgel-coated samples had significantly lower neuronal density than 
the contralateral control at 0-100 µm and 100-200 µm, as well as significantly lower 
neuronal density compared to the 4 week time point in the 400-500 µm bin. 
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Figure 3.8: Immunofluorescence images (a) from each time point and experimental group stained 
with NeuN, a marker for neuronal. Graphs for each time point (b) indicate the average number of 
neuronal nuclei in each 100µm bin for uncoated and microgel-coated samples as a percentage of the 
cells found in the contralateral uninjured control. Symbols indicate: * significant differences between 
uncoated and microgel-coated samples, ‡ significant differences between uncoated and contralateral 
samples, # significant differences between microgel-coated and contralateral samples, ^ significant 





We have engineered a microgel coating for neural electrodes consisting of 
poly(NIPAm-co-AAc-PEG(575)-DA) particles that is applied to the surface of the 
electrodes using crosslinking chemistry and cationic “glue”. Previous work from our lab 
has shown success with the monolayer microgel coatings for reducing cell adhesion and 
protein adsorption [101, 107], as well as significantly reducing acute and chronic 
inflammatory responses [102]. We have also observed moderate effects in reducing 
fibrous capsule formation in chronic implantation [103]. The multilayer coating used in 
this study performed well in vitro with cell adhesion experiments with mixed astrocyte 
and microglia cultures showing a significant reduction in the number of adherent cells 
and amount of cell spreading on microgel-coated electrodes compared to uncoated 
controls. However, the in vivo data obtained from chronic implantation of the electrode 
into the rat cortex indicated only modest improvements in the cellular responses around 
the implanted electrode including variable cell response over time and persistence of 
inflammation and scar formation at chronic time points. At 24 weeks of implantation, 
microgel-coated electrodes exhibited reduced astrocytic and activated macrophage 
staining in the vicinity of the electrode. However, neuronal density close to the electrode 
was reduced for microgel-coated electrodes. 
Cell adhesion studies were performed to compare mixed glial attachment between 
the uncoated and microgel-coated electrode surfaces. The mixed glial cells were chosen 
due to the presence of astrocytes and microglia, two of the main cell types involved in 
inflammation and scar formation. Microglial attachment studies have been performed by 
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others [57] to observe differences in cell attachment to electrode surfaces. Monolayer 
microgel coatings have shown reduced protein adsorption [107, 108] and reduced cell 
adhesion in other applications [101-103]. Quantification of in vitro data of multilayer 
coatings cultured with mixed glial cells showed promising results with significantly 
reduced cell adhesion on the electrode surface when coated with microgel particles. The 
significant reduction in cell spread area suggested the potential of the microgel coating 
for reducing cell adhesion in the early stages of cell-electrode interaction. 
The in vivo data gathered from histological samples indicated a time-dependent 
tissue response surrounding neural electrodes. Staining for GFAP (astrocytes) around 
implanted electrodes at 1 week indicated the intensity1, decay1, and intensity2 parameters 
were higher for microgel-coated samples, indicating increased astrocyte presence around 
the microgel-coated samples initially after implantation. From 1 week to 4 weeks the 
astrocyte staining parameters for uncoated samples increased for intensity1 and decay1 
while decreasing for decay2 while the microgel-coated sample parameters increased for 
intensity1 and decay1. This increase is a well-known response to chronically implanted 
electrodes and has been observed in multiple studies [12, 15, 17] as it is indicative of the 
scar formation that occurs over time around implanted electrodes. The 4 week time point 
showed increased staining for intensity1, decay1, and decay2 parameters on microgel-
coated samples while intensity2 was higher for uncoated samples. These data indicate that 
astrocyte staining corresponding to the area closest to the electrode, was higher in the 
microgel-coated sample while the higher intensity2 value for uncoated samples indicated 
increased astrocyte staining farther from the electrode at distances >100 µm. From 4 to 
24 weeks microgel-coated sample parameters intensity1 and decay1 parameters decreased. 
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All parameters for uncoated samples were higher than microgel-coated samples at 24 
weeks. The change in parameters over time as well as at the 24 week time point indicated 
a reduction in astrocyte presence in response to the microgel-coated electrode, showing 
an improvement in one of the major constituents of the scar formation that occurs in vivo. 
Overall, the data indicate that GFAP staining increases initially and is maintained 
chronically as the intensity values indicate persistence of higher GFAP staining around 
the implanted electrode. These results are consistent with other studies reporting 
increasing astrocyte recruitment over time [12, 15, 64] as well as variation at different 
time points [17, 30] indicating the variable nature of tissue response to implanted 
electrodes.   
  Staining for resident microglia using OX42 / CD11b showed variability over 
time in tissue response to chronically implanted electrodes. At the 1 week time point, 
uncoated samples had higher intensity1 and decay2 parameters while decay1 and intensity2 
were higher for microgel-coated samples. The data indicated higher resident microglial 
staining around uncoated electrodes in first phase of the decay equation corresponding to 
the 0-100 µm distance from the electrode surface as well as faster decay of staining 
intensity in the second phase of the decay equation corresponding to the 100-500 µm 
distance from the implantation site. Conversely, higher microglial staining at the 100-500 
µm distance indicates increased microglial presence away from the electrode site as well 
as faster decay of microglial staining intensity closest to the electrode surface around 
microgel-coated samples. The decay1 parameter for microgel-coated samples increased 
from 1 to 4 weeks, indicating a faster decay in resident microglial presence at short time 
points close to the electrode surface. For the same time frame, uncoated sample decay2 
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decreased indicating a slower decline in the resident microglial staining at distances 100-
500 µm from the electrode surface. By 4 weeks all parameters for microgel-coated 
samples were higher than uncoated samples indicating increased microglial presence 
around microgel-coated samples. From 4 to 24 weeks decay1 decreased for microgel-
coated samples, and at 24 weeks uncoated electrode parameters were higher than 
microgel-coated electrode parameters for intensity1 and decay1 and lower for intensity2. 
The changes at later time points indicate higher microglial staining around uncoated 
samples at distances close to the electrode surface while microgel-coated samples had 
higher staining at distances farther from the electrode surface at 100-500 µm from the 
implant. Overall, the variations in tissue response over time are similar to results 
observed in other studies of microglial response with an initial increase after implantation 
followed by fluctuations over time [30] as the tissue is constantly changing around the 
implant. 
Response of activated microglia to the implanted electrodes also showed temporal 
changes in the reactivity of astrocytes in surrounding tissue. Activated microglia (ED1 / 
CD68) staining parameters showed higher intensity1 and intensity2 for uncoated samples 
at 1 week, indicating higher microglial activation after initial implantation. From 1 to 4 
weeks, the microgel-coated decay1 parameter increased while uncoated decay1 and 
intensity2 decreased, resulting in higher intensity1, intensity2, and decay2 and lower 
decay1 for uncoated samples compared to microgel-coated samples at 4 weeks. These 
data indicate the increased presence of activated microglia around uncoated electrodes 
with parameters associated with both phases of the decay equation, which corresponds to 
distance both close to (0-100 µm) and farther (100-500 µm) from the electrode surface 
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and is consistent with previously reported results [12]. The lower decay1 parameter also 
indicates a slower decay around uncoated samples in the area closest to the electrode. 
From 4 to 24 weeks, parameters for uncoated electrodes increased for intensity1 and 
decay1, while decay1 decreased for microgel-coated samples. At 24 weeks intensity1, 
decay1, and intensity2 were higher and decay2 was lower for uncoated samples. These 
data indicate maintenance of microglial activation around uncoated samples across the 
500 µm analysis area, but also indicate a faster decay rate in staining close to the 
implanted electrode and slower decay rate farther from the electrode surface. The 
variation in ED1 activity over time is consistent with observations in the literature [30] as 
long-term studies have observed a similar response. As with the GFAP and OX42 
markers, each cell response is variable over time with parameters that change between 
time points. 
NeuN stain was used to identify neuronal nuclei in the area around implanted 
electrodes. At 1 week there were significant differences between the uncoated and 
contralateral (uninjured control) NeuN+ counts, as well as between the microgel-coated 
and contralateral samples at 0-100 µm and 100-200 µm for both groups. This indicates a 
decrease in neuronal density close to the electrode surface soon after implantation, and 
this trend is similar to what has been observed in literature [12, 17]. At 4 weeks, the 
neuronal density around uncoated samples was significantly lower than microgel-coated 
samples at 0-100µm, and both groups were significantly lower than the contralateral 
control at the same distance. Additionally, the uncoated samples were significantly lower 
than the contralateral control at 200-300 µm. These data indicate the continued effect of 
the electrode presence in reducing neuronal cell density near the electrode surface, as 
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constant presence of the electrode in the tissue continues to affect neuronal survival [12]. 
At 24 weeks, the microgel-coated samples had significantly lower neuronal density than 
the contralateral control at 0-100 µm and 100-200 µm, as well as significantly lower 
neuronal density compared to the 4 week time point in the 400-500 µm bin. This result 
was unexpected as we had hypothesized that the microgel-coating would improve the 
long-term cell response. We do not know the exact cause for the lower neuronal density 
around microgel-coated samples at 24 weeks. Overall, the data show lower neuronal 
staining levels near the implant, which increase as you move away from the injury. This 
behavior indicates the effect of the environment around the injury, likely a combination 
of physical injury from implantation as well as the resulting inflammatory response and 
cytokine release, which causes neuronal loss near the implant site. This is a significant 
problem for neural electrode function as neurons must be present near the site of the 
electrode for the implant to be functional in receiving neuronal signals. 
Future work with microgel coatings can improve upon the material to make it 
more suitable for chronic neural electrode implantation. Several polymer coatings have 
been developed that demonstrate reduced protein adsorption and astrocytic recruitment 
around the implant [58, 69], and others with reduced impedance and other improvements 
in conductive polymers to improve neuronal signal propagation [109, 110]. One the of 
major responses that occurs after implantation of any material is the formation of scar-
like tissue around the implant as the body tries to separate the implant from the tissue. 
The astrocytes and microglia in the brain contribute to this scar formation and it is 
believed that increased inflammation contributes to the activation of these cell types. 
Further modification of the microgel coatings with immunomodulators to control 
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inflammation may contribute to greater improvements for tissue response to implanted 
electrodes. Release of anti-inflammatory agents can help to mediate the tissue response to 
a greater extent if the inflammation is controlled effectively. Many groups have 
attempted to modulate this inflammatory response with both passive and active release of 
anti-inflammatory factors. Zhong et al. developed a polymer coating with passive release 
of dexamethasone that showed a reduction in GFAP staining intensity, ED1 staining, and 
neuronal loss at 1 week and 4 weeks post-implantation [64].  Mercanzini et al. also 
demonstrated effectiveness of dexamethasone in a short term study to reduce astrocyte 
and microglial recruitment at 3 weeks [67]. Taub et al. showed the effectiveness of 
coatings containing IL-1Ra compared to laminin coatings, demonstrating reductions in 
GFAP staining with the IL-1Ra coating [82]. Others have tried to increase neuronal 
survival and attachment in vitro [55, 100] however these coatings also improve cell 
attachment for unwanted cell types such as astrocytes. Additionally, the studies showing 
improvement in multiple cell types (astrocytes, microglia, and neurons) were only 
performed for short time points ~4 weeks. A recent study has investigated long-term 
effects of Parylene-C coating for reducing cell adhesion on implanted silicon electrodes 
[60]. Although the results demonstrated reduced cell adhesion on the Parylene-C coated 
electrode, the inflammatory response persisted through the 12-week time point.  We 
hypothesized that the composition of our microgel coating, containing temperature 
responsive pNIPAm combined with the “gold-standard” poly(ethylene glycol) for 
reducing cell adhesion, would provide a suitable alternative for reducing cell adhesion. 
Although both the Parylene-C coating presented by Winslow et al and the microgel 
coating presented in this study had reduced cell adhesion in vitro, the long-term in vivo 
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observations indicated maintenance of long-term inflammatory response.  Together, these 
studies indicate that the problem with chronically implanted electrodes goes beyond the 
need for a non-adhesive surface alone, but likely requires additional modification 
including inflammation attenuation. While many of these coatings showed some 
improvement there is no coating that solves all long-term tissue response problems, 
underscoring the need for further research. Our study indicated some improvement on 
certain parameters of GFAP, OX42, and ED1 staining with the microgel coating, similar 
to many of the studies listed above. However, maintaining long-term improvement for 
chronic time points is a difficult task which requires more investigation. 
There are many areas for improvement in the area of neural electrode 
implantation. The response of the tissue surrounding the electrode is variable depending 
on the implant and the time point and continues to change over time. This variable 
environment provides a significant challenge for improving long-term electrode function, 
but we believe further modification of the electrode surface can provide options. Several 
labs have investigated the effects of modified electrode design geometry on the tissue 
response surrounding the electrode. Some groups have shown that while minimizing 
damage using smaller electrodes may provide some positive effects [44], the persistence 
of the electrode in the tissue remains a significant problem [1]. Modification of electrode 
design geometry [39, 111] and insertion techniques [112] to minimize tissue injury and 
blood-brain-barrier disruption [41] may also provide better options. Another area of for 
potential improvement is the choice of electrode materials to improve upon the 
mechanical mismatch [48] that exists between stiff electrodes and soft neural tissue. 
Several groups have shown potential for improvement in tissue response when using 
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materials that adapt after implantation with a resulting electrode that is softer and more 
mechanically similar to the brain tissue than stiff electrodes using computational [113] 
and experimentally validated models [50, 114].  Using electrodes that are untethered has 
also indicated positive results compared to electrodes that are attached to the skull [44]. 
Adding neuron-specific survival and attractant factors [53] may also improve upon the 
recording potential, but these factors must also avoid recruitment of other cell types such 




The findings from many of these studies reiterate the importance of addressing the 
inflammatory response as inflammation is a factor that persists as part of the host 
response to implanted electrodes [21]. Long-term inflammation and microglial activation 
contribute to the foreign body response and failure of electrodes implanted for chronic 
time points [111]. Reduction of the inflammatory response can be achieved by releasing 
anti-inflammatory agents at the most beneficial time point, where specific drugs are 
targeted to be released at a time when the corresponding target molecule is at its peak in 
the inflammatory cascade. The multi-faceted problem of improving long-term electrode 
functionality is a complicated task that will likely involve a combination of targets 
including reducing unwanted cell adhesion from astrocytes and microglia, maintaining 
neuronal survival and presence around the electrode, and reducing inflammation in the 
surrounding tissue. Modification of microgel-coated electrodes with anti-inflammatory 
agents to modulate inflammation around electrodes may provide an effective method for 
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ENGINEERING A PROTEASE-DEGRADABLE PEG-MALEIMIDE 
COATING WITH ON-DEMAND RELEASE OF IL-1RA TO 
IMPROVE TISSUE RESPONSE TO NEURAL ELECTRODES 
Introduction 
 Knowledge gained from the studies in Aim 1 contributed to a more thorough 
understanding of the necessity for improved coatings on neural electrodes. While the 
microgel coating was not successful in improving the long-term tissue response to 
implanted neural electrodes as measured by cellular stains for microglia and astrocytes, 
the information gained from the study indicated a need to develop a coating with more 
than just a passive non-fouling surface modification. Rather, it is important to engineer a 
coating that will possess a combination of non-fouling properties in addition to an 
immunomodulatory aspect. As discussed in the literature review, there have been studies 
that developed coatings with incorporated anti-inflammatory agents with mixed results. 
Collectively, these results indicate the need to engineer a better coating to improve the 
tissue response to the implanted electrodes. We hypothesized that a coating comprising a 
protein adsorption/cell adhesion-resistant layer with controlled on-demand release of the 
anti-inflammatory agent IL-1Ra would improve the tissue response and neuronal survival 
near the implant-tissue interface.  
First, we started with a material that has been characterized for use as a non-
fouling surface. Poly(ethylene glycol) (PEG) is a synthetic polymer that is used as a 
biocompatible material for implantable devices [115]. PEG has been widely characterized 
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as a non-fouling material because of the reduced protein adsorption and reduced cell 
adhesion on the PEG surface [116-118]. Additionally, PEG-based coatings have been 
applied to neural electrodes with promising results in vitro including reduced cell 
adhesion and protein adsorption [59, 119]. Finally, PEG-based materials have been 
successfully used for delivery of cells and bioactive molecules including dexamethasone 
[120], proteins [121], fibroblasts [93], VEGF and pancreatic islets [98], among others.   
Another important factor in choosing a material for coating is the ability to 
engineer an on-demand response to inflammatory stimuli. Protease degradable hydrogels 
are a promising option as the inflammatory cascade causes up-regulation of many 
proteases including MMPs [83, 84]. Specifically, PEG hydrogels that degrade in response 
to proteases such as MMP-1 and MMP-2 are of interest for this work [93, 122], 
especially because these MMPs have been implicated as an important part of the 
inflammatory cascade in the brain [85, 89]. Recent work by Patterson and Hubbell 
provided thorough characterization of protease-degradable peptide sequences, including 
cleavage by MMPs, that can be used as crosslinkers for PEG macromers in PEG 
hydrogels [122]. As part of this characterization, the study analyzed over two dozen 
peptide sequences for use with protease-degradable hydrogels. Based on this paper, we 
chose two protease-sensitive, crosslinking peptides for use in this engineered hydrogel 
coating: GCRDGDQGIAGFDRCG (GDQ) and GCRDVPMSMRGGDRCG (VPM). 
GDQ has very slow degradation kinetics (kcat = 0.79 s
-1
 for MMP-1 and no observable 
degradation for MMP-2), whereas VPM has fast degradation kinetics (kcat = 5.25 s
-1
 for 
MMP-1 and 4.82 s
-1
 for MMP-2) in response to MMP challenge. Importantly, these 
peptides contain cysteines at both end of the molecule; the free thiol in these residues 
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reacts rapidly with the maleimide group in the PEG macromers to produce a crosslinked 
hydrogel. These PEG-mal hydrogels and crosslinking peptides have been previously 
characterized and used successfully by our lab for other drug and cell delivery 
applications [97, 98]. 
Finally, we chose to incorporate IL-1 receptor antagonist (IL-1Ra) as the anti-
inflammatory agent to be released. IL-1 is up-regulated in brain injury [73, 77, 79], and 
IL-1Ra has been shown to be an effective molecule to improve neuronal survival in 
addition to reducing inflammation in the brain [81]. Additionally, IL-1Ra has been used 
in humans to treat several diseases involving inflammation and has a good record of 
safety [80].  
Combining all of these important considerations, we have engineered a novel 
coating with three essential components:  
1) a protein adsorption- and cell adhesion-resistant PEG hydrogel;  
2) incorporated anti-inflammatory IL-1Ra, known to reduce inflammation in brain injury 
models; 
3) protease-sensitive crosslinkers for on-demand release of IL-1Ra in response to 
proteases which are up-regulated during inflammation. 
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Materials and Methods 
PEG-maleimide Coating of Electrodes 
Electrodes were purchased from NeuroNexus Technologies (CM16 A4x4-4mm-
200-200-1250) and consist of a silicon substrate with iridium wires and active sites. Each 
electrode is 4-mm long with four active sites on each of four prongs, and each active site 
has an area of 1250 mm
2
. Electrodes were cleaned to remove contaminants remaining 
after manufacture using serial 5-min incubations in trichloroethylene (JT Baker), acetone 
(Sigma-Aldrich), and methanol (Sigma-Aldrich). Electrodes were then rinsed with 
absolute ethanol (Decon Labs). The surface was functionalized using a silane-based 
adhesion layer that is grafted onto the silicon oxide layer of the electrode. Briefly, the 
electrodes were incubated for 2 hours in 2.5% silane-PEG-maleimide (Nanocs Inc.) in 
DMSO, then rinsed with absolute ethanol and PBS. Multi-treatment PEG-mal coatings 
were deposited using a dip-coating technique developed for this project. Electrodes were 
incubated in solution with crosslinking peptide, either GDQ or VPM, for 2 minutes, 
rinsed with PBS, incubated for 2 minutes in 4-arm, 20 kDa PEG-maleimide, and rinsed 
with PBS. Alternating incubations in crosslinking peptide followed by PEG were 
repeated to achieve the desired number of treatments per coating, with each set of peptide 
and PEG considered as one complete treatment. For samples presenting only the PEG 
hydrogel (designated as PEG), the samples were coated with six treatments of PEG-mal 
and GDQ, whereas the coatings containing IL-1Ra (PEG + IL-1Ra) were coated with two 
treatments of PEG-mal and GDQ followed by four treatments of PEG-mal/IL-1Ra and 
VPM. Coating deposition was verified by X-ray photoelectron spectroscopy (XPS). 
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While the coatings do incorporate different crosslinkers, this hydrogel system with both 
crosslinkers has been extensively characterized by our lab and there are minimal 
differences in hydrogel structure. Silicon wafers were used as a surrogate for the Si 
substrate of the electrodes, and coating thickness was analyzed by wet-cell ellipsometry 
of coatings on Si wafers by Dr. Yang Wei and Dr. Robert Latour at Clemson University. 
Ellipsometry measurements were performed using Sopra GES5 variable angle 
spectroscopic ellipsometer (Sopra Inc., Palo Alto, CA) and the accompanying GESPack 
software package. Briefly, a total of six spectra for at least two test points on each sample 
in deionized water were scanned from 350 nm to 800 nm at 10 nm intervals using an 
incident angle of 70°. The thickness of the test substrate was estimated from a model and 
determined using the regression method in Sopra’s Winelli (ver. 4.08) software. 
In Vitro Analysis of Cell Adhesion 
Either uncoated or PEG-coated silicon wafers were placed in individual wells of a 
96-well plate.  The samples (n = 4 per group) were washed three times with 70% ethanol 
followed by three washes with sterile PBS. Mixed astrocyte and microglial cells were 
added to each well at a density of 50,000 cells/cm
2
. The samples were cultured in 
DMEM/F12 (Invitrogen) and 10% FBS (Invitrogen) at 37ºC and 5% CO2 for 24 h. 
Samples were stained with LIVE/DEAD stain (Invitrogen) and imaged with a 20X Apo 
Nikon objective (0.75 NA). Cell spread area on the electrode surface was measured using 
ImageJ software (NIH). 
Cytokine Release Analysis 
Si wafers were coated as described above with 6 treatments of PEG-mal and GDQ 
for PEG samples and 2 treatments of PEG-mal and GDQ followed by 4 treatments of 
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PEG-mal + IL-1Ra and VPM for the PEG + IL-1Ra samples. The samples (n = 4 per 
group) were placed in a 96-well plate and washed three times with 70% ethanol followed 
by three times with sterile PBS. Cells were seeded at a density of 30,000 cells/well in 
DMEM + N2 supplement (Life Technologies) in an ultra-low attachment cell culture 
plate.  Cells were incubated overnight at 37ºC and 5% CO2 before rinsing the samples and 
transferring the samples to a new well to avoid detecting cytokine release from distressed 
cells that remained in suspension. The samples were stimulated with 10 ng/ml 
granulocyte macrophage colony stimulating factor (GM-CSF) to promote cytokine 
secretion [57] and incubated for 48 hours. Levels of IL-1β and TNF-α were analyzed 
using ELISA (R&D Systems). 
IL-1Ra Release Characterization 
Si wafer samples (n = 4 per group) were coated as described above with two 
treatments of PEG-mal with GDQ crosslinker followed by 4 treatments of PEG-mal + IL-
1Ra with VPM crosslinker. The samples were placed in a 96-well plate and washed three 
times with 70% ethanol followed by three washes with sterile PBS. The samples were 
incubated with supernatant from LPS-stimulated mixed glia cultures or naive media and 
supernatant samples were collected at specified time points for analysis using an ELISA 
(R&D Systems). 
Electrode Implantation 
NIH guidelines for the care and use of laboratory animals (NIH Publication #85-
23 Rev. 1985) were observed. All surgical procedures were approved by the Institutional 
Animal Care and Use Committee at the Georgia Institute of Technology. Male Sprague-
Dawley rats (Charles River Laboratories) weighing 200-300g were anesthetized with 
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isofluorane (n = 8 per group). The surgical site was shaved and hair removed with Nair, 
then cleaned with isopropyl alcohol and chlorohexaderm before mounting the animal 
onto a stereotactic frame. Marcaine (0.15 mL of 0.5%) was injected subcutaneously at the 
site of incision. A midline incision 2-3 cm long was made in the scalp and the periosteum 
retracted to expose the cranium. Three 1 mm-diameter pilot holes were made around the 
skull, two posterior to bregma on either side of the midline and one anterior and right of 
bregma. A 4.7 mm stainless steel bone screw (Fine Science Tools 19010-00) was inserted 
into each of the pilot holes, with each screw penetrating the skull but leaving about 1-2 
mm of each screw head remaining out of the skull to serve as an attachment point for the 
headcap. The craniotomy for electrode insertion was made anterior to and left of bregma 
using a 2.7 mm trephine bit (Fine Science Tools 18004-27). The dura was resected and 
folded away from the insertion site. The electrode was held in the stereotactic frame 
above the 2.7 mm hole and slowly lowered into the cortex, careful to avoid any large 
vasculature in the surgical area. Agarose gel (1.5% w/v, SeaKem) was filled into the 
opening around the electrode and dental acrylic (OrthoJet) was used to anchor the 
electrode assembly to the skull. The scalp incision was closed and triple-antibiotic 
ointment was applied to the wound. Each animal was given an injection of 0.03 mg/kg 
sustained release buprenorphine for pain relief allowed to recover from anesthesia under 
a heat lamp. All animals were fully ambulatory post recovery and no complications were 
observed. 
 At 4 weeks the animal was anesthetized with ketamine/xylazine/acepromazine  
(50, 10, and 1.67 mg/kg body weight respectively). For samples used for histological 
sections (n = 8 per group), the animal underwent transcardial perfusion with 200 mL 
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0.4% papaverine HCl in 0.9% NaCl, followed by 50 mL of 0.9% NaCl, and 200 mL of 
4% paraformaldehyde in phosphate buffer. After perfusion, the rat was decapitated and 
excess tissue removed from the skull before placing the intact skull into 4% 
paraformaldehyde overnight. The following day, the intact skull was moved to 30% 
sucrose in PBS. After one day in 30% sucrose, the skull cavity was opened and the brain 
was carefully removed. Any electrodes remaining in the brain were removed from the 
tissue before placing the whole brain into a 50 mL conical tube with 30% sucrose 
overnight until the brain sank to the bottom of the tube. The purpose of the sucrose 
solution was to serve as a cryoprotectant for the brain during immunostaining analyses. 
Following sinking to the bottom of the 50 mL conical tube, samples were embedded in 
OCT and frozen using isopentane in liquid nitrogen. For samples to be used for qRT-PCR 
analysis (n = 7 per group), the animal was anesthetized with 
ketamine/xylazine/acepromazine prior to transcardial perfusion with 100 mL cold PBS 
followed by 100 mL 30% sucrose in PBS. Upon finishing the perfusion, the rat was 
decapitated and the brain promptly removed from the skull. A 2-mm biopsy punch was 
used to remove brain samples which were immediately placed in RNAlater (Life 
Technologies) and stored at -20ºC until analysis by qRT-PCR. 
Histological Evaluation 
Samples were sectioned in 16-mm thick sections using a cryostat and stained for 
various cell markers as indicated in Table 4.1. All primary antibodies were visualized 
with Alexa-Fluor 488 secondary antibody (Invitrogen) and counterstained with DAPI for 
cell nuclei recognition. Upon completion of staining, all slides were imaged using a 10X 
Nikon objective (0.30 NA) and SPOT Advanced software (Diagnostic Instruments). 
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Analysis of inflammatory and neuronal markers was conducted in a similar manner to 
Aim 1. 
Table 4.1: Antibodies used for immunofluorescence analysis 
Antibody Supplier Cell / Tissue Identified 
Glial fibrillary acidic protein (GFAP) Abcam ab7260 Astrocytes 
NeuN Millipore MAB377 Neuronal nuclei 
OX42 / CD11b Chemicon CBL1512 Resident microglia 
ED1 / CD68 AbD Serotec MCA341R Activated microglia 
Alexa Fluor - Rat IgG Life Technologies A11006 Blood brain barrier breach 
CS56 Sigma C8035 Chondroitin sulfate 
 
 
Quantitative Reverse Transcriptase – Polymerase Chain Reaction (qRT-PCR) 
Samples for qRT-PCR were stored in RNAlater buffer (Qiagen) until processing. 
Individual biopsy punch (2 mm diameter) samples from the electrode implantation site 
and the uninjured contralateral hemisphere were collected from each animal. Samples 
were placed in Qiazol (Qiagen) and homogenized using a Lab Gen 7 tissue homogenizer 
(Cole Palmer) for ~1 minute. Tissue homogenate was placed in a QIAshredder column 
followed by total RNA extraction with the RNEasy MinElute Cleanup Kit (Qiagen). All 
RNA samples were tested for quality using a Nanodrop and had a 260/280 value of 2 or 
higher. Subsequent cDNA conversion was completed using the RT
2
 First Strand Kit 
(Qiagen).  Total cDNA, corresponding to mRNA expression, was analyzed using the 
Fluidigm BioMark system. 16 gene targets (Table 4.2) were analyzed to observe changes 
in inflammation as well as neural cell markers, GAPDH was used as a housekeeping 
gene. The Ct values were normalized using ΔΔCt method, normalizing to the 
contralateral uninjured hemisphere and the housekeeping gene. Results are presented as 
fold change in gene expression compared to the uninjured contralateral hemisphere per 
group. 
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Table 4.2: Gene Targets for qRT-PCR Analysis 
IL-1α Interleukin - 1α MMP-2 
Matrix metalloproteinase – 2, 3, 9, 13 IL-1β Interleukin - 1β MMP-3 
IL-1Ra Interleukin -1 receptor 
antagonist 
MMP-9 
IL-6 Interleukin - 6 MMP-13 
IL-10 Interleukin - 10 NGF Nerve growth factor 
MCP-1 Monocyte chemoattractant 
protein - 1 
BDNF Brain derived neurotrophic factor 
TNF-α Tumor necrosis factor - α CNTF Ciliary neurotrophic factor 
IFN-γ Interferon-γ GFAP Glial fibrillary acidic protein 
 
Statistical Analysis 
Data presented are mean +/- standard error. All analyses were performed using 
GraphPad Prism 6.0. Statistical analyses for differences between thickness of multiple 
treatments of PEG hydrogel, in vitro cell adhesion, and cytokine release were performed 
using one-way ANOVA with Tukey’s multiple comparison test. Statistical analysis of 
differences between PEG and PEG + IL-1Ra coating thickness was analyzed using an 
unpaired t-test. Curve fit parameters for immunostaining intensity curves were analyzed 
for normal distribution using the D’Agostino & Pearson normality test. As these 
parameters were found be not normally distributed, the curve-fit parameters were 
analyzed using a Kruskal-Wallis test with Bonferroni-Dunn’s multiple comparison test to 
test for differences among groups. Analysis of NeuN data was performed using a 2-way 
repeated measures ANOVA with Tukey’s multiple comparison test. PCR data was 
analyzed using a one-way ANOVA with Tukey’s multiple comparison to test for 





Characterization of PEG Hydrogel Coatings 
 
Silicon surfaces (electrode or Si wafer) were coated with the PEG-mal hydrogel 
coating. Figure 4.1a shows a diagram of the predicted structure of the coating consisting 
of silane-PEG-mal, a protease degradable crosslinker, and PEG-maleimide molecules. 
Figure 4.1b shows XPS survey spectra for uncoated and 6-treatment PEG hydrogel-
coated surfaces. As seen in the narrow band scans in Figure 4.1c, clear shifts in the C1s 
peak demonstrate PEG-coated samples having a higher portion of C-C, H bonds as a 
result of coating deposition. The thickness of the coatings was analyzed by wet-cell 
ellipsometry. Figure 4.2a show that the thickness of the PEG coating increases with 
increasing treatment deposition, and a 6-treatment coating is approximately 30 nm thick, 
a reasonable measurement given the size of the coating components. Figure 4.2b shows 
the difference in thickness between a 6-treatment coating of PEG and a 6-treatment 
coating with 2 treatments PEG and 4 treatments PEG + IL-1Ra, with the latter being 
thicker. The increased thickness for the PEG + IL-1Ra is not surprising given the 
incorporation of the anti-inflammatory protein (17 kDa, corresponding to a 3 nm 






Figure 4.1: PEG coatings applied to the surface of electrodes. (a) Chemical structure of 
the PEG coating applied to the surface of the silicon substrate. (b) XPS spectra of 
uncoated (left) and PEG coated (right) electrodes. (c) Detailed carbon shifts of the 




Figure 4.2: PEG coating thickness analyses. (a) Thickness of the coating increases with 
increasing number of treatments applied to the surface. (b) Incorporating IL-1Ra yields a 
thicker coating than with the PEG alone. * = p<0.05, ** = p<0.01. 
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In Vitro Cell Adhesion 
 Silicon wafer samples were coated with one, two, or six treatments of PEG 
hydrogel using GDQ as the crosslinking peptide. Uncoated and PEG-coated surfaces 
were seeded with mixed glial cells (astrocytes + microglia) to evaluate cell adhesion to 
the coating. Cells were stained with Live/Dead stain with >90% live cells on the surfaces. 
Analysis of these results indicated that the PEG hydrogel reduces cell attachment and 
spreading compared to uncoated controls (Figure 4.3a). The PEG coated samples had 
significantly reduced cell adhesion  and cell spreading when analyzed by total number of 
attached cells (Figure 4.3b), total area per attached cell (Figure 4.3c), and total area 
covered by attached cells (Figure 4.3d).  The results indicated that the 6-treatment coating 
yielded the best reduction of cell adhesion and cell spreading. Additionally, the 2-
treatment coating provided sufficient non-fouling behavior so that a 2-treatment non-
degradable PEG coating can be used as a “base” coating for the additional 4-treatment 







Figure 4.3: Cell adhesion on varying PEG layers. (a) Live/Dead stain of cell 
adhesion on uncoated and PEG coated surfaces with 1, 2, or 6 treatment cycles. Scale 
bar = 250 µm. (b) Total number of cells adhered, (c) area per attached cell, and (d) 
total area covered by adhered cells on the surface is significantly lower on PEG 
coated surfaces than uncoated surfaces. ** = p<0.01, **** = p<0.0001. 
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In Vitro Inflammatory Cytokine Release 
 
Untreated and coated surfaces were tested to evaluate the release of cytokines, 
specifically IL-1β (Figure 4.4a) and TNF-α (Figure 4.4b), from mixed glial cells in 
response to stimulation with GM-CSF for 48 hours. These results indicated that levels of 
IL-1β were significantly higher on uncoated surfaces than those coated with PEG or PEG 
+ IL-1Ra (detection limit = 5 pg/ml). TNF-α levels on the uncoated surface were 
significantly higher while levels for the coated surfaces were below the detection limit 
(detection limit = 5 pg/ml). These results indicate that the PEG and PEG + IL-1Ra 
coatings reduce the release of inflammatory cytokines compared to uncoated surfaces. 
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Figure 4.4: Cytokine release on uncoated, PEG, and PEG+ IL-1Ra coated surfaces 
in response to GM-CSF stimulation. (a) IL-1β was significantly higher on uncoated 
surfaces. (b) TNF-α was significantly higher on the uncoated surface, and levels on 
coated surfaces were below detection limits. * = p<0.05, ** = p<0.01. 
 69 
 
IL-1Ra Release  
In order to assess the stimulus-responsive release of IL-1Ra, we examined the 
release of IL-1Ra over time using an ELISA (Figure 4.5). Samples were placed in 
conditioned media from cells stimulated with LPS (to release proteases) or naïve media. 
The release curve showed that samples incubated with the LPS-stimulated cell culture 
media had an increasing release over time following a simple hyperbolic curve. Samples 








Figure 4.5: IL-1Ra release curve shows that IL-1Ra release is higher with 
LPS-stimulated cell media compared to media alone.  
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Inflammatory Marker Expression In Vivo 
 
 Histological sections for each experimental condition (n = 8 per group) were 
analyzed using the markers described in Table 4.1 and intensity profiles were analyzed 
using the curve fit approached described in Aim 1. A pilot study demonstrated no gross 
differences in inflammatory markers along the mid-shaft of the electrode, so all analyses 
were performed using sections at approximately 500 µm from the cortex surface. It is 
also important to note that there is considerable animal-to-animal variability in these 
experiments, an issue which must be considered when analyzing the data for implanted 
electrodes.  
Resident microglia were stained with OX42/CD11b (Figure 4.6). There were no 
significant differences among groups for Intensity1, Intensity2, and Decayslow. However, 
the Decayfast parameter was significantly higher for PEG + IL-1Ra compared to PEG 
coatings, indicating that the intensity of resident microglial staining near the implant 
interface (0-100 μm) decays at a faster rate for PEG+IL-1Ra samples compared to other 
conditions. This is an important finding because it indicates that presence of resident 
microglial cells decreases at a faster rate close to the electrode surface for the PEG + IL-
1Ra group. 
Activated microglia were stained with ED1/CD68 (Figure 4.7) and astrocytes 
were stained with GFAP for glial fibrillary acidic protein (Figure 4.8). These stains 
showed no significant differences among groups for any parameters. This result indicates 
that neither the PEG coating nor the coating releasing IL-1Ra altered the distribution of 
these cell types in the vicinity of the implanted electrode.  
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Chondroitin sulfate antibody (CS56) was used to stain for glycosaminoglycans 
(GAG, Figure 4.9), which are a major extracellular matrix component of the astroglial 
scar. The Decayslow parameter was significantly lower for the PEG + IL-1Ra group 
compared to uncoated samples indicating that the amount of GAG staining decreases at a 
slow rate at distances far from the electrode surface (>100 µm).  
Rat IgG was used as a marker for blood-brain barrier (BBB) breach (Figure 4.10), 
as this molecule permeates into brain tissue from comprised vasculature. The Intensity1 
parameter was significantly lower for PEG + IL-1Ra compared to uncoated surfaces, 
while the Intensity2 parameter significantly lower for PEG + IL-1Ra compared to PEG 
alone. These differences indicate that the amount of IgG staining is lower around PEG + 
IL-1Ra coated electrodes, indicating a lower level of BBB breach. There were no 





Figure 4.6: Immunofluorescence analysis of resident microglia (OX42). (a) 
Immunofluorescence images (left) and corresponding intensity scale (right) for 
uncoated, PEG, and PEG + IL-1Ra (n=8 per group). (b) Parameter plots indicate 
differences in each parameter of Equation 1 for each experimental group. The initial 
decay parameter is significantly higher for PEG + IL-1Ra compared to PEG alone.  
** = p<0.01. 
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Figure 4.7: Immunofluorescence analysis of activated microglia (ED1). (a) 
Immunofluorescence images (left) and corresponding intensity scale (right) for 
uncoated, PEG, and PEG + IL-1Ra (n=8 per group). (b) Parameter plots indicate 
differences in each parameter of Equation 1 for each experimental group.  
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Figure 4.8: Immunofluorescence analysis of glial fibrillary acidic protein (GFAP) for 
astrocytes. (a) Immunofluorescence images (left) and corresponding intensity scale 
(right) for uncoated, PEG, and PEG + IL-1Ra (n=8 per group). (b) Parameter plots 




Figure 4.9: Immunofluorescence analysis of chondroitin sulfate (CS56) to 
observe glycosaminoglycans at the injury site. The Decayslow parameter was 
significantly lower for PEG + IL-1ra compared to uncoated samples. Other 
parameters were not significantly different. * = p < 0.05. 
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Figure 4.10: Immunofluorescence analysis of rat IgG for blood brain barrier 
breach. For both stains, the Decayslow parameter was significantly lower for PEG 
+ IL-1ra compared to uncoated samples. Intensity2 was also significantly lower 
for PEG + IL-1Ra compared to uncoated electrodes. Other parameters were not 




To analyze neuronal survival, the number cells positive for NeuN (neuronal 
nuclei) were counted per specified 50- or 100- µm bin at a distance of 0 – 500 µm from 
the implant insertion site (Figure 4.11). Neuronal survival increased for both PEG and 
PEG + IL-1Ra coated electrodes compared to uncoated controls. For the 0-50 µm bin, the 
number of NeuN+ cells in the PEG + IL-1Ra group was not significantly different from 
the uninjured contralateral control. In the 50-100 µm bin, both PEG and PEG + IL-1Ra 
were not significantly different from the uninjured control. At distances 100+ µm from 
the interface, all three groups were not significantly different from the uninjured control. 
This data indicates increased neuronal survival around the electrode within the first 100 
µm from the implant interface for the coated electrodes. This location is most critical for 
maintaining electrode functionality because the neurons closest to the electrode will 
provide the electrical signals that will be received by the electrode.  
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Figure 4.11: Neuronal survival around the electrode. Uninjured control is indicated 
by the green dotted line. PEG + IL-1Ra was not significantly different from the 
uninjured control for any distance analyzed as indicated by the red arrows. At 50 – 
100 µm from the tissue/implant interface, PEG and PEG + IL-1Ra groups were not 
significantly different from the uninjured control as indicated by the blue and red 
arrows, respectively. All groups were not significantly different from the uninjured 
control at distances greater than 100 µm from the implant. 
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Quantitative RT-PCR Analysis 
 Quantitative RT-PCR was used to compare gene expression from brains (n = 7 
per group) implanted with uncoated, PEG, or PEG + IL-1Ra electrodes, as well as the 
contralateral uninjured control. Gene expression analysis was conducted for the following 
gene targets: IL-1α, IL-1β, IL-1Ra, IL-6, IL-10, TNF-α, IFN-γ, MCP-1, MMP-2, MMP-
3, MMP-9, MMP-13, NGF, GFAP, BDNF, and CNTF. The heat map generated by the 
Fluidigm software is seen in Figure 4.12. The fold change differences between the genes 
can be seen in Figure 4.13, with the genes showing significant differences between 





Figure 4.12: Heat map of the Ct values generated by the Fluidigm BioMark system. 
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Figure 4.13: Fold change values for the 16 gene targets analyzed with qRT-PCR. 




We have engineered a polymer coating for neural electrodes that consists of a 
non-fouling coating made of poly(ethylene glycol) that contains a protease-degradable 
crosslinker and an anti-inflammatory agent, IL-1Ra, that is released on-demand in 
response to proteases associated with the inflammatory response. The conclusions from 
Aim 1 showed that a non-fouling coating alone does not yield significant improvement to 
the tissue and inflammatory response to implanted neural electrodes [124].  This result 
indicated a need to incorporate an anti-inflammatory agent into the coating in an attempt 
to reduce the inflammatory response to implanted neural electrodes. 
In the present study, we coated the surface of the electrodes with a multi-layer 
PEG-maleimide coating. The coating was characterized using XPS and wet-cell 
ellipsometry to verify presence of the coating on the surface as well as increasing coating 
thickness corresponding with increasing treatment deposition, respectively. We 
characterized resistance to cell-adhesion by coating silicon wafer samples and plating 
them with mixed glial cells for 24 hours. This in vitro analysis indicated that PEG coated 
surfaces with one, two, or six treatments were resistant to cell adhesion. The total number 
of attached cells, average area per attached cell, and total cell attached area on each 
sample were all significantly lower on coated samples compared to uncoated samples. 
Additional in vitro characterization was completed to observe differences in cytokine 
release from mixed glial cells plated on the uncoated, PEG, and PEG + IL-1Ra surfaces. 
After plating the cells and stimulating the cells with GM-CSF for 48 hours, the cytokine 
levels were analyzed using ELISA. Cells plated on uncoated surfaces released 
significantly more IL-1β and TNF-α than PEG or PEG + IL-1Ra coated surfaces. These 
 84 
data indicate that the PEG-coated surfaces reduce inflammatory cytokine release from 
mixed glial cells. This result is likely due to the fact that the coated surfaces have less cell 
adhesion than uncoated surfaces, thereby containing fewer cells to release cytokine in 
response to the GM-CSF stimulus. This result is consistent with previous work with non-
fouling/cell adhesion-resistant coatings [57]. We also characterized the release of IL-1Ra 
from coated samples using ELISA. PEG + IL-1Ra samples were plated with media from 
LPS-stimulated mixed glial cells or PBS. Stimulation of mixed glial cells with LPS 
stimulates release of cytokines and proteases which cause cleavage of the protease-
degradable crosslinking peptides in the PEG hydrogel, releasing IL-1Ra. The coatings 
incubated in conditioned media from LPS-treated cultures released significantly more IL-
1Ra over time than the samples incubated in PBS, indicating the protease-dependent 
release of IL-1Ra from the degradable coating. Incubating samples in naïve media (not 
exposed to cells) showed similar release results compared to PBS. Collectively, the in 
vitro results indicated a promising cell adhesion-resistant and anti-inflammatory coating 
to be used for in vivo analysis. 
For the in vivo portion of this study, uncoated, PEG, and PEG+IL-1Ra coated 
electrodes were implanted in the brain of rats for 4 weeks to evaluate the in vivo response 
of the brain to implanted electrodes. Samples were collected, cryosectioned, and stained 
for markers to indicate cell response to the implanted electrode as well as blood brain 
barrier breach. The samples for OX42, ED1, GFAP, CS56, and IgG were analyzed using 
similar methods to Aim 1 where the intensity curve for each sample was fit with a curve 
using Equation 1. Samples stained with OX42 / CD11b for resident microglia had no 
differences in Intensity1, Intensity2, and Decayslow parameters between the groups. 
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However, the Decayfast parameter was significantly higher for PEG + IL-1Ra compared to 
PEG coatings, indicating that the intensity of resident microglial staining near the implant 
interface (0-100 μm) decays at a faster rate for PEG+IL-1Ra samples. This difference in 
the OX42 Decayfast parameter indicates that the IL-1Ra has an effect on microglial 
recruitment to the electrode / tissue interface. While the initial intensity does not vary, the 
reduction in microglial staining at 0 – 100 µm from the implant shows an improvement in 
the cell response and microglial recruitment to the area around the electrode.  
Data for ED1/CD11b and GFAP staining, indicating activated microglia and 
astrocytes, respectively, showed no significant differences for any of the parameters 
among the groups. We hypothesized that the anti-inflammatory factor incorporated into 
the PEG-coating would reduce the inflammatory response in the surrounding tissue. 
However, persistence of activated microglia around the implant for all experimental 
groups indicates that the IL-1Ra does not prevent microglial activation. Since microglial 
activation is an important part of the inflammatory cascade, it is apparent that 
inflammation persists in the tissue. Additionally, we hypothesized that the non-fouling 
PEG surface would reduce astrocyte recruitment and subsequent scar formation; 
however, this did not occur in the rat model. This is an important finding because it 
indicates a need for better in vitro evaluation techniques. The 2D cell culture system is a 
good starting point, but further evaluation with more complex in vitro systems is 
necessary to determine if a particular coating can perform well in vivo. 
 CS56 staining for chondroitin sulfate indicates the presence of 
glycosaminoglycans, and IgG shows areas of blood brain barrier breach around the injury 
site. The Decayslow parameter was significantly higher for uncoated samples compared to 
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PEG+IL-1Ra for CS56, indicating a faster decrease of CS56 staining at areas >100μm 
from the injury site. The lack of differences among the groups for CS56 staining is 
consistent with results from other studies [64].  For the IgG stain, the lower Intenisty1 and 
Intensity2 parameters for PEG + IL-1Ra compared to uncoated and PEG coated 
electrodes, respectively, indicates that the amount of BBB breach around the PEG + IL-
1Ra coated electrodes is significantly reduced compared to the uncoated and PEG 
electrodes. This is an important finding because literature indicates that the persistence of 
the electrode in the tissue and the subsequent continued BBB breach is correlated with 
persistence of inflammation in the brain [18], and reducing the effect of BBB breach may 
reduce inflammatory responses in the long term. At this point, it is not known if the 
reduction in IgG staining / BBB breach is due to a reduction of the initial inflammatory 
response, faster healing response over time, or a combination of the two in the presence 
of the IL-1Ra, but this would be an interesting aspect to explore in future studies. 
Notably, Bellamkonda and colleagues recently demonstrated that reduced BBB breach 
correlates with improved electrode recording function [18]. Whether the PEG coatings 
and IL-1Ra release improve electrode function will need to be examined in future studies.  
Finally, NeuN staining for neuronal nuclei showed differences in neuronal 
survival among the three groups. We observed increased neuronal survival for the PEG + 
IL-1Ra group at 0 - 50 µm as well as increased survival for PEG and PEG+IL-1Ra at 50 - 
100 µm. The neuronal survival for all groups was not significantly different from the 
uninjured control at distances greater than 100 μm from the electrode surface. This is an 
important finding because neurons are necessary for electrode functionality. If the 
neurons surrounding the implant do not survive after electrode insertion, then the 
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electrode cannot receive any electrical signals from the surrounding tissue, rendering the 
device useless. Increasing neuronal survival is essential to maintaining long-term 
electrode function.  The ideal response of the brain would result in no neuronal death 
upon implantation of a neural electrode. However, improvement within the first 100 µm 
is a promising finding as electrodes can record neuronal activity to a radius of ~100 
microns or more from the electrode surface [125]. 
Analysis of gene expression in the brain around the electrode implantation site 
yielded important insights into the tissue responses to implanted electrodes. Of the 16 
genes that were analyzed, only three had significant differences among groups. For IL-6, 
the fold change gene expression was significantly higher in the PEG + IL-1Ra group 
compared to the PEG group. While IL-6 is traditionally identified as a pro-inflammatory 
cytokine [79], there is evidence to suggest that it plays a role in activation of downstream 
cell-survival and anti-apoptotic factors [78]. The up-regulation of MMP-2 in the PEG + 
IL-1Ra group compared to the uncoated group is an interesting finding. MMP-2 is found 
in activated astrocytes [126], which is consistent with the presence of recruited astrocytes 
around the implanted electrode. It is unknown why the MMP-2 levels are up-regulated in 
the PEG + IL-1Ra group but not in the PEG or uncoated, considering the inflammatory 
markers for astrocytes and activated microglia showed no differences between the 
groups. The increase in MMP-2 in the PEG + IL-1Ra group is also contradictory to some 
extent, as MMP-2 is implicated in promoting BBB breach [126], but the IgG staining 
intensity was significantly lower for PEG + IL-1Ra samples. It is possible that the release 
of MMP-2 is occurring as part of a redundant system in response to down-regulation of a 
different inflammatory cytokine, as there are many redundant signaling pathways in the 
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cell biology. Alternatively, MMP-2 up-regulation may reflect the activation of tissue 
repair mechanisms. Regardless, the presence of MMP in the injury site validates the use 
of this protease-degradable coating as the MMPs will cause desired degradation of the 
coating and release of the anti-inflammatory therapeutic.  
Gene expression of neural-specific markers showed significantly higher 
expression of cilliary neurotrophic factor (CNTF) in PEG + IL-1Ra group compared to 
PEG and uncoated groups. CNTF is important for neuronal survival and neurite 
outgrowth [127]. Interestingly, research has shown that IL-1β is required for the 
production of CNTF [128], indicating that inflammatory cytokines can play a role in both 
pro-inflammatory activation as well as anti-inflammatory cytokine activation 
downstream. The lack of differences in NGF and BDNF were surprising given the 
increased neuronal survival found in the PEG + IL-1Ra group, however this may also 
indicate that other factors such as CNTF or others not investigated here may play a more 
significant role in neuronal survival. Overall, the results from the gene expression studies 
are generally consistent with the findings from the immunofluorescence analysis, 
showing persistence of inflammation and increased expression of a neuronal survival 
gene. These results indicate possible targets for future research into inflammation and 
neuronal survival in the brain.  
The findings from this study lead to several important conclusions about neural 
electrode research. First, the coating presented here had promising in vitro results with 
regards to reduced cell adhesion and reduced cytokine release on PEG-coated samples. 
However, these results did not translate well with regards to inflammatory cell 
recruitment in vivo. Astrocyte and activated microglial recruitment did not vary between 
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groups and the resident microglial recruitment analysis showed only slight improvement 
for PEG+IL-1Ra over the PEG coating alone or uncoated electrodes. Also, the CS56 
staining showed no improvement with the PEG coatings compared to uncoated samples.  
IgG staining, a surrogate for BBB breach, showed reduced BBB breach around PEG + 
IL-1Ra electrodes at all distances analyzed (0-500 µm). The gene expression analysis 
yielded interesting results that were consistent with the overall findings from the 
immunofluorescence analysis, and also provide information that may lead to a better 
understanding of targets for future therapies. Additionally, this study also showed 
promising results with regards to improving neuronal survival on coated surfaces which 
is an important finding for improving long-term electrode functionality.  
It is important to note the lack of translation between in vitro and in vivo success. 
The in vitro screening used here is similar to other studies [57, 69, 119, 129] using 2D 
cell culture methods to demonstrate the non-fouling characteristics of the coating. 
However, the lack of translation between in vitro and in vivo success indicates the need 
for a better screening system prior to implantation. The 2D in vitro system does not 
emulate the complex systems that exist in the brain. While 3D culture systems do exist 
[130-133], there is still a lack of vasculature and the associated problems that arise with 
blood-brain barrier breach as well as limited inflammatory stimuli due to the lack of BBB 
breach and surrounding full tissue injury. The data from this study indicates a need to 
develop better in vitro validation methods that better emulate the complex tissue response 
for future studies. 
Additionally, it is important to consider the options for analyzing the tissue 
response to implanted neural electrodes. The use of immunostaining markers to stain 
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tissue sections and then evaluation at variations of staining intensity is a very coarse 
measurement of the tissue response. While it is important to understand the cell response 
around the electrode, there must also be other methods used to gain a complete picture of 
the tissue response.  Finally, this work indicates the need for a multi-component coating. 
The PEG+IL-1Ra had better results overall than PEG alone, with both coatings 
performing better than the uncoated electrodes with respect to neuronal survival. The 
tissue response to implanted electrodes is a complicated problem that will likely need a 
complex solution including non-fouling coatings in addition to bioactive molecules 
including anti-inflammatory agents as well as others to support neuronal survival to yield 
the best response. Overall, it is important to consider the multi-faceted problems that 
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SUMMARY OF CONCLUSIONS 
There are several important conclusions that can be drawn from this work to add 
to the knowledge in the field. First, the thermo-responsive microgel coating performed 
well in vitro with reduced cell adhesion on the surface of coated electrodes compared to 
uncoated controls. Although the in vitro results were promising, the long-term tissue 
response to microgel coated electrodes implanted in the brain indicated a lack of effective 
reduction in inflammation in vivo. Based on these results, we hypothesized that future 
studies would need to incorporate a bioactive factor.   
Using the information we learned from the microgel study, we decided to move 
forward with the PEG-maleimide coating with protease-degradable crosslinker to release 
an incorporated IL-1Ra anti-inflammatory agent. This coating also performed well in 
vitro with studies to analyze cell attachment, inflammatory cytokine release, and IL-1Ra 
release from coated samples. Subsequent in vivo studies indicated only minor 
improvement in one parameter of the inflammatory cytokine markers. However, IgG 
staining, a surrogate for BBB breach, was reduced for PEG + IL-1Ra coatings compared 
to uncoated electrodes, suggesting that this anti-inflammatory agent improves some 
inflammatory outcomes. Consistent with this observation, neuronal survival was 
significant and maintained in response to coated electrodes, with the best improvement 
observed for the PEG + IL-1Ra group. This is an important finding because neuronal 
survival is essential to long-term functionality of the electrode since the neuronal 
electrical signals are the signals that need to be received at the electrode surface. 
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Additionally, results from the gene expression analysis study indicate potential targets for 
future therapies which may be useful in producing better modifications to improve the 
tissue response to implanted electrodes.  
One important aspect of this research that must be considered moving forward is 
the concept of biological significance vs. statistical significance. While a statistically 
significant result may pass a mathematical evaluation of differences from a control or 
untreated sample, it is important to analyze these results in the context of what will 
actually be useful to patients. Will a statistically significant change of p<0.05 provide 
enough modification to improve an implanted device in a patient? The only way to 
determine such statistical vs. biological significance is with live, functional testing to see 
if modified devices do indeed work longer and better than their unmodified counterparts. 
It is also important to consider how the intervention itself will affect the recording 
functionality. In the case of this coating, there is only a finite amount of IL-1Ra available 
on the device. Once the coating is degraded and all IL-1Ra has been released, the system 
may require further intervention in order to maintain the improved tissue response. There 
are options such as implantable pumps and systemic drug dosing, but these interventions 
will run into issues of increased clinical visits, systemic side effects from drugs, and 
problems with patient compliance. The ideal coating or modification would make the 
implant “invisible” to the body, such that it could exist in the tissue without provoking an 
immune response. Until we find that “magic bullet,” however, it is important to continue 
to research promising options.   
An additional important finding from this research is the necessity for better in 
vitro methods of analysis. The microgel-coated and PEG-coated surfaces performed well 
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in cell adhesion tests showing less cell adhesion on coated surfaces, indicating the non-
fouling nature of the coatings. Additionally, the cytokine analysis of the PEG surfaces 
further indicated the effectiveness of this coating to reduce the inflammatory response. 
However, these results did not translate to effective reduction of inflammatory cell 
markers in the brain, leading to the need to develop a better option for in vitro analysis 
option.  
Overall, this work contributes to the knowledge of the field because it describes, 
in detail, two different coatings that were used to try to improve the tissue response to 
implanted neural electrodes. Although the microgel coating was not successful, the PEG 
coating shows promise for future studies, especially with the increased neuronal survival 
observed when incorporating IL-1Ra. With further modification including other bioactive 
factors, we may be able to develop a coating that will lead to reduced inflammation as 






First and foremost, it is important to understand that the tissue response to 
implanted materials in the brain is complicated and it is unlikely that the issue of 
maintaining long-term electrode functionality can be solved with a single approach. As 
with the rest of the body, the brain is a complex system with multiple cell types, 
incorporated vasculature, and immune and inflammatory response to foreign materials. 
The brain has the additional caveat of being an immuno-privileged site due to the mass 
transfer limitations of the blood brain barrier, leaving fewer options in terms of 
pharmacological intervention than would be available in the rest of the body. In order to 
maintain electrode functionality, it is important to mediate the recruitment of cells such as 
microglia and astrocytes to the implant site to reduce the inflammatory response and 
subsequent scar formation around the electrode. In addition to reducing inflammatory cell 
recruitment, it is also important to reduce neuronal cell death around the implant site. 
Finally, the blood-brain barrier breach is also an important factor than must be taken into 
consideration when analyzing the response to an implanted electrode.  
 Another important consideration of this research indicates the need for more 
thorough evaluation of the in vitro response to electrode coatings before moving forward 
with in vivo studies. While 2D and 3D culture systems have been used previously, they 
do not provide a complete picture of the response to electrode surfaces. It is difficult to 
recapitulate all aspects of brain response, including vasculature, BBB breach, subsequent 
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injury and inflammatory response, cytokine release, and cell recruitment. I believe the 
vasculature and associated BBB breach is an especially important aspect to address, 
although it is difficult to recapitulate in an in vitro model. It is difficult to know how a 
device will perform in vivo until you actually implant it in a living animal model, but 
more work towards developing a more complete in vitro system may provide an 
alternative for electrode evaluation. 
 In addition to developing new 3D cell culture based in vitro evaluation methods, 
there are also other potential alternatives that may serve to complement the knowledge 
gained from an in vitro cell system. Current methods already exist to evaluate gene 
expression in tissues, such as the analysis presented in this thesis. By analyzing gene 
expression in conjunction with the functionality of implanted electrodes in animals, it 
may be possible to determine specific genes that are up- or down-regulated in the animals 
with the best functional outcome. These genes can then be used as targets for future 
screening tools. With recent advances in gene expression analysis, it is possible to 
analyze large sample sets using small quantities of starting material to analyze gene 
expression from small samples as small as single-cell replicates. High throughput 
screening of future electrode modifications using an in vitro assay to measure gene 
expression may provide an additional level of understanding when analyzing cell 
response and looking at the response of specific gene targets that are found to be 
significant for improved electrode functionality. Combining the analysis of these gene 
targets with other in vitro evaluation methods may yield a better overall picture of the 
potential for the electrode to be successful in an animal model. 
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 In addition to new screening methods, it is important to further investigate the on-
demand release aspect for bioactive factors. In a system such as the one used for this 
research, the coating is degraded to release the anti-inflammatory agent in response to 
inflammation in the brain. This is an important characteristic because the bioactive factor 
is being release on an as-needed basis, and not just as a bolus response at initial 
implantation. By incorporating several bioactive factors with different stimuli as triggers 
for degradation, it may be possible to control the responsiveness of the coating based on 
the different cytokines that are released in different phases of the inflammatory cascade. 
 Finally, it is important to realize that the complex problems surrounding the use of 
cortical electrodes may be solved by looking into completely different methods of 
analyzing neuronal activity in the brain. Techniques using voltage sensitive dyes or gene 
therapy may provide a less-invasive method for analyzing the brain’s response to a 
particular stimulus. Other non-invasive methods such as electroencephalogram (EEG) 
may one day be able to pinpoint activity in a specific region of the brain, allowing for a 
non-invasive measure of neuronal firing in the area of interest for cortical electrodes. 
While the current electrode technology does have the potential to be useful in future BMI 
developments, it is important to analyze all existing technologies to determine which one 
will provide the best overall outcome for patients, even if that means moving to a new 
technology altogether. 
 Overall, this problem will require a multi-component approach. This research 
shows the validity of non-fouling PEG coatings to improve neuronal survival compared 
to uncoated electrodes. Additionally, adding the anti-inflammatory agent IL-1Ra further 
increased the neuronal survival, indicating the importance for including bioactive factors 
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to mediate the inflammatory response. By developing new systems that can mediate the 
inflammatory response in a directed fashion, it is possible to improve the tissue response 
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